<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1" specific-use="sps-1.9" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
	<front>
		<journal-meta>
			<journal-id journal-id-type="nlm-ta">Rev Saude Publica</journal-id>
			<journal-id journal-id-type="publisher-id">rsp</journal-id>
			<journal-title-group>
				<journal-title>Revista de Saúde Pública</journal-title>
				<abbrev-journal-title abbrev-type="publisher">Rev. Saúde Pública</abbrev-journal-title>
			</journal-title-group>
			<issn pub-type="ppub">0034-8910</issn>
			<issn pub-type="epub">1518-8787</issn>
			<publisher>
				<publisher-name>Faculdade de Saúde Pública da Universidade de São Paulo</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="other">00249</article-id>
			<article-id pub-id-type="doi">10.11606/s1518-8787.2022056003904</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Original Article</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Factors associated with HIV/syphilis co-infection initiating of antiretroviral therapy</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4942-5195</contrib-id>
					<name>
						<surname>Simões</surname>
						<given-names>Luana Andrade</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>I</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-3505-4626</contrib-id>
					<name>
						<surname>Mendes</surname>
						<given-names>Jullye Campos</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>I</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-7002-4428</contrib-id>
					<name>
						<surname>Silveira</surname>
						<given-names>Micheline Rosa</given-names>
					</name>
					<xref ref-type="aff" rid="aff2"><sup>II</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-4936-8650</contrib-id>
					<name>
						<surname>Costa</surname>
						<given-names>André Moura Gomes da</given-names>
					</name>
					<xref ref-type="aff" rid="aff3"><sup>III</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-0760-4424</contrib-id>
					<name>
						<surname>Lula</surname>
						<given-names>Mariana Dias</given-names>
					</name>
					<xref ref-type="aff" rid="aff2"><sup>II</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4340-0659</contrib-id>
					<name>
						<surname>Ceccato</surname>
						<given-names>Maria das Graças Braga</given-names>
					</name>
					<xref ref-type="aff" rid="aff2"><sup>II</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1">
				<label>I</label>
				<institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
				<institution content-type="orgdiv1">Faculdade de Farmácia</institution>
				<institution content-type="orgdiv2">Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica</institution>
				<addr-line>
					<named-content content-type="city">Belo Horizonte</named-content>
					<named-content content-type="state">MG</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original">Universidade Federal de Minas Gerais. Faculdade de Farmácia. Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica. Belo Horizonte, MG, Brasil</institution>
			</aff>
			<aff id="aff2">
				<label>II</label>
				<institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
				<institution content-type="orgdiv1">Faculdade de Farmácia</institution>
				<institution content-type="orgdiv2">Departamento de Farmácia Social</institution>
				<addr-line>
					<named-content content-type="city">Belo Horizonte</named-content>
					<named-content content-type="state">MG</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Belo Horizonte, MG, Brasil</institution>
			</aff>
			<aff id="aff3">
				<label>III</label>
				<institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
				<institution content-type="orgdiv1">Faculdade de Engenharia</institution>
				<institution content-type="orgdiv2">Programa de Pós-Graduação em Engenharia Elétrica</institution>
				<addr-line>
					<named-content content-type="city">Belo Horizonte</named-content>
					<named-content content-type="state">MG</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original">Universidade Federal de Minas Gerais. Faculdade de Engenharia. Programa de Pós-Graduação em Engenharia Elétrica. Belo Horizonte, MG, Brasil</institution>
			</aff>
			<author-notes>
				<corresp id="c01"> Correspondence: Luana Andrade Simões Universidade Federal de Minas Gerais Av. Presidente Antônio Carlos, nº 6.627, sala 1.023-B2 31270-901 Belo Horizonte, MG, Brasil E-mail: <email>lu.unife@gmail.com</email>
				</corresp>
				<fn fn-type="con">
					<p>Authors’ Contribution: Study conception and planning: LAS, MGBC, MRS, JCM, MDL, AMGC. Data collection, analysis and interpretation: LAS, MGBC, MRS, JCM, MDL, AMGC. Manuscript elaboration or review: LAS, MGBC, MRS, JCM, MDL, AMGC. Final version approval: LAS, MGBC, MRS, JCM, MDL, AMGC. Public responsibility for the article’s content: LAS, MGBC, MRS, JCM, MDL, AMGC.</p>
				</fn>
				<fn fn-type="conflict">
					<p>Conflict of Interest: The authors declare there is no conflict of interest.</p>
				</fn>
			</author-notes>
			<pub-date date-type="pub" publication-format="electronic">
				<day>24</day>
				<month>06</month>
				<year>2022</year>
			</pub-date>
			<pub-date date-type="collection" publication-format="electronic">
				<year>2022</year>
			</pub-date>
			<volume>56</volume>
			<elocation-id>59</elocation-id>
			<history>
				<date date-type="received">
					<day>27</day>
					<month>05</month>
					<year>2021</year>
				</date>
				<date date-type="accepted">
					<day>10</day>
					<month>08</month>
					<year>2021</year>
				</date>
			</history>
			<permissions>
				<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
					<license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
				</license>
			</permissions>
			<abstract>
				<title>ABSTRACT</title>
				<sec>
					<title>OBJECTIVE</title>
					<p> To evaluate the prevalence and factors associated with HIV/syphilis co-infection in people initiating antiretroviral therapy in Belo Horizonte, capital of the state of Minas Gerais.</p>
				</sec>
				<sec>
					<title>METHODS</title>
					<p> A sectional section of a prospective cohort study was carried out with people living with HIV, treatment-naive, initiating antiretroviral therapy, older than 16 years, and in follow-up treatment at specialized HIV/Aids care services in Belo Horizonte. Sociodemographic, behavioral, clinical, laboratory and pharmacological treatment-related data were obtained through interviews, medical records, and information systems for logistical control of antiretroviral medications and laboratory tests. The dependent variable was the first episode of active syphilis, recorded by the physician in clinical records, within 12 months after beginning of the antiretroviral therapy. Factors associated with HIV/syphilis co-infection were assessed using binary multiple logistic regression.</p>
				</sec>
				<sec>
					<title>RESULTS</title>
					<p> Among the 459 individuals included, a prevalence of 19.5% (n = 90) of sexually transmitted infections (STI) was observed, with syphilis (n = 49) being the most frequent STI in these individuals. The prevalence of HIV/syphilis co-infection was 10.6% (n = 49), and the associated independent factors were alcohol use (OR = 2.30; 95%CI: 1.01–5.26), and having a diagnosis of other sexually transmitted infections (OR = 3.33; 95%CI: 1.24–8.95).</p>
				</sec>
				<sec>
					<title>CONCLUSIONS</title>
					<p> There was a high prevalence of HIV/syphilis co-infection in people living with HIV initiating antiretroviral therapy in Belo Horizonte. HIV/syphilis co-infection was associated with behavioral and clinical factors, such as alcohol use and diagnosis of other sexually transmitted infections. Prior knowledge about the factors associated with this co-infection may support the decisions of health professionals engaged in the care to people living with HIV, with regard to timely diagnosis, guidance, follow-up and adequate treatment, both for syphilis and HIV.</p>
				</sec>
			</abstract>
			<kwd-group xml:lang="en">
				<kwd>HIV Infections</kwd>
				<kwd>Syphilis</kwd>
				<kwd>Coinfection, epidemiology</kwd>
				<kwd>Risk Factors</kwd>
				<kwd>Antiretroviral Therapy, Highly Active</kwd>
				<kwd>Cross-Sectional Studies</kwd>
			</kwd-group>
			<counts>
				<fig-count count="2"/>
				<table-count count="6"/>
				<equation-count count="0"/>
				<ref-count count="29"/>
			</counts>
		</article-meta>
	</front>
	<body>
		<sec sec-type="intro">
			<title>INTRODUCTION</title>
			<p>Sexually transmitted infections (STI) are considered one of the major public health problems in Brazil and worldwide. Their prevention and control entail individual and public benefits, including the decrease in risks of transmission of the human immunodeficiency virus (HIV)<sup><xref ref-type="bibr" rid="B1">1</xref></sup>.</p>
			<p>STIs reach a high rate among sexually active people, and occur silently thus contributing to their dissemination. The syphilis, caused by the etiologic agent <italic>Treponema pallidum</italic>, and HIV infection<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup> have the most common transmission routes, and social determinants.</p>
			<p><italic>T. pallidum</italic> infection can increase the viral load and decrease the number of TCD4+ lymphocytes, resulting in increased morbidity and mortality in people living with HIV. Moreover, the presence of HIV may affect the transmission of syphilis, its clinical course, response to treatment, and may change its diagnosis<sup><xref ref-type="bibr" rid="B4">4</xref></sup>.</p>
			<p>Some Brazilian studies found that factors associated with HIV/syphilis co-infection were age, marital status, male gender, low education, multiple partners, presence of STIs, irregular use of condoms, men who have sex with men (MSM), among others<sup><xref ref-type="bibr" rid="B5">5</xref></sup>. In international studies, the associated factors were male gender, migrants, low education, age, multiple partners, irregular condom use, MSM, illicit drug use, presence of STIs, among others<sup><xref ref-type="bibr" rid="B10">10</xref></sup>.</p>
			<p>This study aimed to assess the prevalence of HIV/syphilis co-infection in HIV-positive individuals at the beginning of antiretroviral therapy (ART) in Belo Horizonte, Minas Gerais, Brazil, and to identify factors associated with HIV/syphilis co-infection.</p>
		</sec>
		<sec sec-type="methods">
			<title>METHODS</title>
			<p>We carried out a cross-sectional study of a prospective cohort, called Project ECOART “<italic>Efetividade da terapia antirretroviral em pessoas vivendo com HIV/tuberculose, HIV/hanseníase ou HIV/leishmaniose visceral no Brasil</italic>” (Effectiveness of antiretroviral therapy in people living with HIV/tuberculosis, HIV/leprosy, or HIV/visceral leishmaniasis in Brazil). The project was approved by the research ethics committee of the <italic>Universidade Federal de Minas Gerais</italic> (protocol CAAE 31192914.3.3001.5124, opinion CEP 769.085) and of the participating services. Research was conducted in compliance with the instructions of Resolution 466/2012 by the National Health Council.</p>
			<p>Sample selection was non-randomized, as all eligible individuals were invited to participate in the study. Recruitment occurred between September 2015 and October 2017.</p>
			<p>The study was carried out at three specialized care services (<italic>Serviços de Assistência Especializada</italic>, SAE) in HIV/Aids of the Unified Health System (SUS). SAE I is an outpatient clinic of a state reference hospital for the treatment of infectious diseases and health dermatology; SAE II is a testing and counseling center (<italic>Centro de Testagem e Aconselhamento</italic>, CTA); SAE III is a reference SAE for the care of infectious and parasitic diseases.</p>
			<p>The eligibility criteria were: individuals of both genders, aged 16 years or older, diagnosed with HIV regardless of the time of diagnosis and the clinical condition of the individual, starting ART (from zero to six months of treatment), without previous pharmacological treatment of HIV infection, and who were being followed-up at one of the three selected services. All participants agreed to participate in the study and signed the informed consent form.</p>
			<p>The dependent variable was the first episode of active syphilis recorded by the physician in the medical record within 12 months after initiation of ART.</p>
			<p>The independent variables related to sociodemographic, behavioral, clinical, laboratory, and pharmacological treatment information were obtained through face-to-face interviews, data collection from clinical records, the Logistic Medication Control System (<italic>Sistema de Controle Logístico de Medicamentos,</italic> Siclom), and the National CD4+/CD8+ Lymphocyte Count and HIV Viral Load Network Laboratory Test Control System (<italic>Sistema de Controle de Exames Laboratoriais da Rede Nacional de Contagem de Linfócitos</italic> CD4+/CD8+ <italic>e Carga Viral do HIV</italic>, Siscel).</p>
			<p>The age of individuals was stratified into age groups for descriptive analysis, and as a continuous variable in logistic regression. The variable self-reported color or ethnicity was stratified into white, black, yellow, brown, or indigenous. Marital status was dichotomized into single/divorced/widowed or married/common-law marriage. Education was categorized as up to 9 years, 10 to 12 years, and 13 years or more of formal education for descriptive analysis, and in two categories for logistic regression (up to 9 years, 10 years or more). We also investigated the existence of children, whether or not they have a job, their own income, private health insurance, place of residence, and economic class.</p>
			<p>The economic class variable was evaluated according to Brazilian criteria, such as high (A-B), intermediate (C) and low (D-E). Here, individuals are classified by socioeconomic groups according to possession of comfort items, and the family head’s level of education. For analysis, the variable was categorized into high (A-B) and intermediate-low (C-D-E).</p>
			<p>In the evaluation of behavioral variables and lifestyle habits, we analyzed the existence of a fixed sexual partner within 12 months after starting ART, alcohol use in the month before the baseline interview, tobacco use at the time of the interview, use of illicit drugs ever in life (marijuana, cocaine, crack, and others, such as ecstasy and glue sniffing), and condom use in the last month and during the last sexual intercourse.</p>
			<p>We analyzed the average time of HIV diagnosis by self-report, the initial and final clinical classification of the individual - categorized as A (asymptomatic), B (symptomatic), and C (Aids-defining clinical condition), according to the criteria of the adapted Centers for Disease Control and Prevention (CDC)<sup><xref ref-type="bibr" rid="B13">13</xref></sup> , the presence of comorbidities, presence of other previous and current STIs, presence of mucous lesions (oral, genital, or anal), viral load, and TCD4 lymphocyte count, according to the Siscel data, mean duration of ART, and treatment regimens, according to the Siclom data. Treatment regimens were categorized as tenofovir/lamivudine/efavirenz (TLE), tenofovir/lamivudine/dolutegravir (TLD), and other (any other antiretroviral regimen). Non-adherence was assessed by self-report, using the question “Have you missed the medication in the last 15 days (yes; no)?”</p>
			<p>Descriptive analysis was carried out using frequency distribution for categorical variables, and measures of central tendency and variability for continuous variables. Pearson’s chi-square or Fischer’s exact test was used to compare proportions between categorical variables, and the T-test was used to compare means between continuous variables. The multiple binary logistic regression model was used to assess factors associated with HIV/ syphilis co-infection.</p>
			<p>All variables were subjected to collinearity tests. The results of logistic regression were presented by odds ratio (OR), 95% confidence interval (95%CI), and p value. Variables that showed p value of 0.20 or less in the bivariate analysis were included in the multivariate model. The stepwise backward conditional method was used to obtain the final model. The Hosmer-Lemeshow test and the area under the Receiver Operating Characteristics (ROC) curve were used to verify the model fit. Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) software, version 22.0, and R Studio, version 4.0.2. All analyses were performed with a 5% significance level.</p>
		</sec>
		<sec sec-type="results">
			<title>RESULTS</title>
			<p>A total of 459 individuals were enrolled in the study (<xref ref-type="fig" rid="f01">Figure</xref> 1). Among the sociodemographic characteristics of the study general population, it was observed that 81.5% of the individuals were male, with a mean age of 34.7 years (SD = 10.9), and a predominance of the age range of 20 to 34 years (53.4%). Most individuals were single, divorced, or widowed (79.7%), and had 10 years or more of formal education (74.3%). Regarding behavioral characteristics, 27.5% of the individuals used tobacco at the time of the interview, 64.1% used alcohol in any quantity in the month before the interview, 48.1% used illicit drugs at some time in their lives. As for the potential source of HIV infection, more than half (51%) were MSM.</p>
			<p>
				<fig id="f01">
					<label>Figure</label>
					<caption>
						<title>Diagram of the individuals included in the study.</title>
					</caption>
					<graphic xlink:href="1518-8787-rsp-56-59-gf01.tif"/>
					<attrib>ART: antiretroviral therapy.</attrib>
				</fig>
			</p>
			<p>Among the participants, 25.5% reported not using condoms in the last month, and 21.4% in the last sexual intercourse. Clinical classification A (asymptomatic) was observed in 63.4% of individuals at the first visit, and in 80.8% at the last visit. At the beginning of treatment, most participants (88.9%) had detectable viral load and, at the end of 12 months of ART, only 6.8% had detectable viral load. The percentage of missing data was 30.5%. At the beginning of ART, we observed that 26.1% of the individuals had TCD4 lymphocyte counts below 200 cells/mm<sup><xref ref-type="bibr" rid="B3">3</xref></sup>, and 20.9% started treatment with clinical conditions indicative of Aids. Regarding treatment-related characteristics, the mean time to ART initiation was 78.5 days (SD = 58.97); 63.4% of individuals were using the TDF/3TC/EFV regimen; 14.8% reported non-adherence to treatment; and, 70.8% had been diagnosed with HIV for more than three months (<xref ref-type="table" rid="t1">Table 1</xref>).</p>
			<p>
				<table-wrap id="t1">
					<label>Table 1</label>
					<caption>
						<title>Sociodemographic, clinical, behavioral characteristics, life habits, and treatment of PLHIV, Belo Horizonte, Minas Gerais, 2015–2018 (n = 459).</title>
					</caption>
					<table frame="hsides" rules="groups">
						<colgroup>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left" rowspan="3">Characteristics</th>
								<th colspan="2" rowspan="2">Total n = 459</th>
								<th colspan="4">HIV/ syphilis co-infection</th>
								<th rowspan="3">p</th>
							</tr>
							<tr>
								<th colspan="2">Yes n = 49</th>
								<th colspan="2">No n = 410</th>
							</tr>
							<tr>
								<th>n</th>
								<th>%</th>
								<th>n</th>
								<th>%</th>
								<th>n</th>
								<th>%</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td align="center" colspan="8"><bold>Sociodemographic</bold></td>
							</tr>
							<tr>
								<td>Sex</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.018<sup>a</sup></td>
							</tr>
							<tr>
								<td>Male</td>
								<td align="center">374</td>
								<td align="center">81.5</td>
								<td align="center">46</td>
								<td align="center">93.9</td>
								<td align="center">328</td>
								<td align="center">80.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Female</td>
								<td align="center">85</td>
								<td align="center">18.5</td>
								<td align="center">3</td>
								<td align="center">6.1</td>
								<td align="center">82</td>
								<td align="center">20.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Age (years)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.573</td>
							</tr>
							<tr>
								<td>16–19</td>
								<td align="center">18</td>
								<td align="center">3.9</td>
								<td align="center">1</td>
								<td align="center">2.0</td>
								<td align="center">17</td>
								<td align="center">4.1</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>20–34</td>
								<td align="center">245</td>
								<td align="center">53.4</td>
								<td align="center">26</td>
								<td align="center">53.1</td>
								<td align="center">219</td>
								<td align="center">53.4</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>35–49</td>
								<td align="center">145</td>
								<td align="center">31.6</td>
								<td align="center">14</td>
								<td align="center">28.6</td>
								<td align="center">131</td>
								<td align="center">32.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>≥ 50</td>
								<td align="center">51</td>
								<td align="center">11.1</td>
								<td align="center">8</td>
								<td align="center">16.3</td>
								<td align="center">43</td>
								<td align="center">10.5</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Color/ethnicity</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.874<sup>a</sup></td>
							</tr>
							<tr>
								<td>Brown</td>
								<td align="center">222</td>
								<td align="center">48.4</td>
								<td align="center">21</td>
								<td align="center">42.9</td>
								<td align="center">201</td>
								<td align="center">49.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>White</td>
								<td align="center">108</td>
								<td align="center">23.5</td>
								<td align="center">13</td>
								<td align="center">26.5</td>
								<td align="center">95</td>
								<td align="center">23.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Black</td>
								<td align="center">106</td>
								<td align="center">23.1</td>
								<td align="center">14</td>
								<td align="center">28.6</td>
								<td align="center">92</td>
								<td align="center">22.4</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yellow</td>
								<td align="center">15</td>
								<td align="center">3.3</td>
								<td align="center">1</td>
								<td align="center">2.0</td>
								<td align="center">14</td>
								<td align="center">3.4</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Indigenous</td>
								<td align="center">3</td>
								<td align="center">0.7</td>
								<td align="center">0</td>
								<td align="center">0.0</td>
								<td align="center">3</td>
								<td align="center">0.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">5</td>
								<td align="center">1.1</td>
								<td align="center">0</td>
								<td align="center">0.0</td>
								<td align="center">5</td>
								<td align="center">1.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Marital status</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.271</td>
							</tr>
							<tr>
								<td>Single/divorced/widowed</td>
								<td align="center">366</td>
								<td align="center">79.7</td>
								<td align="center">42</td>
								<td align="center">85.7</td>
								<td align="center">324</td>
								<td align="center">79.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Married/commonwealth marriage</td>
								<td align="center">93</td>
								<td align="center">20.3</td>
								<td align="center">7</td>
								<td align="center">14.3</td>
								<td align="center">86</td>
								<td align="center">21.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Children</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.297</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">162</td>
								<td align="center">35.3</td>
								<td align="center">14</td>
								<td align="center">28.6</td>
								<td align="center">148</td>
								<td align="center">36.1</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">297</td>
								<td align="center">64.7</td>
								<td align="center">35</td>
								<td align="center">71.4</td>
								<td align="center">262</td>
								<td align="center">63.9</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Formal education (years)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.043<sup>a</sup></td>
							</tr>
							<tr>
								<td>≤ 9</td>
								<td align="center">117</td>
								<td align="center">25.5</td>
								<td align="center">11</td>
								<td align="center">22.4</td>
								<td align="center">106</td>
								<td align="center">25.9</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>10–12</td>
								<td align="center">178</td>
								<td align="center">38.8</td>
								<td align="center">12</td>
								<td align="center">24.5</td>
								<td align="center">166</td>
								<td align="center">40.5</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>≥ 13</td>
								<td align="center">163</td>
								<td align="center">35.5</td>
								<td align="center">26</td>
								<td align="center">53.1</td>
								<td align="center">137</td>
								<td align="center">33.4</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">1</td>
								<td align="center">0.2</td>
								<td align="center">0</td>
								<td align="center">0.0</td>
								<td align="center">1</td>
								<td align="center">0.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Job</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.694</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">269</td>
								<td align="center">58.6</td>
								<td align="center">30</td>
								<td align="center">61.2</td>
								<td align="center">239</td>
								<td align="center">58.3</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">190</td>
								<td align="center">41.4</td>
								<td align="center">19</td>
								<td align="center">38.8</td>
								<td align="center">171</td>
								<td align="center">41.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Own income</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.087<sup>a</sup></td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">373</td>
								<td align="center">81.3</td>
								<td align="center">41</td>
								<td align="center">83.7</td>
								<td align="center">332</td>
								<td align="center">81.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">85</td>
								<td align="center">18.5</td>
								<td align="center">7</td>
								<td align="center">14.3</td>
								<td align="center">78</td>
								<td align="center">19.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">1</td>
								<td align="center">0.2</td>
								<td align="center">1</td>
								<td align="center">2.0</td>
								<td align="center">0</td>
								<td align="center">0.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Economic class</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.306<sup>a</sup></td>
							</tr>
							<tr>
								<td>High (A-B)</td>
								<td align="center">162</td>
								<td align="center">35.3</td>
								<td align="center">20</td>
								<td align="center">40.8</td>
								<td align="center">142</td>
								<td align="center">34.6</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Intermediate (C)</td>
								<td align="center">212</td>
								<td align="center">46.2</td>
								<td align="center">23</td>
								<td align="center">46.9</td>
								<td align="center">189</td>
								<td align="center">46.1</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Low (D-E)</td>
								<td align="center">73</td>
								<td align="center">15.9</td>
								<td align="center">4</td>
								<td align="center">8.2</td>
								<td align="center">69</td>
								<td align="center">16.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">12</td>
								<td align="center">2.6</td>
								<td align="center">2</td>
								<td align="center">4.1</td>
								<td align="center">10</td>
								<td align="center">2.4</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Private health plan</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.511</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">121</td>
								<td align="center">26.4</td>
								<td align="center">11</td>
								<td align="center">22.4</td>
								<td align="center">110</td>
								<td align="center">26.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">338</td>
								<td align="center">73.6</td>
								<td align="center">38</td>
								<td align="center">77.6</td>
								<td align="center">300</td>
								<td align="center">73.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Place of residence</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.656<sup>a</sup></td>
							</tr>
							<tr>
								<td>Belo Horizonte</td>
								<td align="center">404</td>
								<td align="center">88.0</td>
								<td align="center">44</td>
								<td align="center">89.8</td>
								<td align="center">360</td>
								<td align="center">87.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Belo Horizonte Metropolitan Area</td>
								<td align="center">49</td>
								<td align="center">10.7</td>
								<td align="center">4</td>
								<td align="center">8.2</td>
								<td align="center">45</td>
								<td align="center">11.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Other municipalities</td>
								<td align="center">6</td>
								<td align="center">1.3</td>
								<td align="center">1</td>
								<td align="center">2.0</td>
								<td align="center">5</td>
								<td align="center">1.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td align="center" colspan="8"><bold>Behavioral and life habits</bold></td>
							</tr>
							<tr>
								<td>Fixed sexual partner within 12 months after ART</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.619<sup>a</sup></td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">218</td>
								<td align="center">47.5</td>
								<td align="center">22</td>
								<td align="center">44.9</td>
								<td align="center">196</td>
								<td align="center">47.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">187</td>
								<td align="center">40.7</td>
								<td align="center">23</td>
								<td align="center">46.9</td>
								<td align="center">164</td>
								<td align="center">40.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">54</td>
								<td align="center">11.8</td>
								<td align="center">4</td>
								<td align="center">8.2</td>
								<td align="center">50</td>
								<td align="center">12.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Use of alcohol in the month before the interview</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.435<sup>a</sup></td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">294</td>
								<td align="center">64.1</td>
								<td align="center">36</td>
								<td align="center">73.5</td>
								<td align="center">258</td>
								<td align="center">62.9</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">162</td>
								<td align="center">35.3</td>
								<td align="center">13</td>
								<td align="center">26.5</td>
								<td align="center">149</td>
								<td align="center">36.3</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">3</td>
								<td align="center">0.7</td>
								<td align="center">0</td>
								<td align="center">0.0</td>
								<td align="center">3</td>
								<td align="center">0.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Current use of tobacco</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.600</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">126</td>
								<td align="center">27.5</td>
								<td align="center">15</td>
								<td align="center">30.6</td>
								<td align="center">111</td>
								<td align="center">27.1</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">333</td>
								<td align="center">72.5</td>
								<td align="center">34</td>
								<td align="center">69.4</td>
								<td align="center">299</td>
								<td align="center">72.9</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Use of illicit drugs in life ever</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.493<sup>a</sup></td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">221</td>
								<td align="center">48.1</td>
								<td align="center">27</td>
								<td align="center">55.1</td>
								<td align="center">194</td>
								<td align="center">47.3</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">236</td>
								<td align="center">51.4</td>
								<td align="center">22</td>
								<td align="center">44.9</td>
								<td align="center">214</td>
								<td align="center">52.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">2</td>
								<td align="center">0.4</td>
								<td align="center">0</td>
								<td align="center">0.0</td>
								<td align="center">2</td>
								<td align="center">0.5</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Condom use in the last month</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.156</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">248</td>
								<td align="center">54.0</td>
								<td align="center">31</td>
								<td align="center">63.3</td>
								<td align="center">217</td>
								<td align="center">52.9</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">117</td>
								<td align="center">25.5</td>
								<td align="center">13</td>
								<td align="center">26.5</td>
								<td align="center">104</td>
								<td align="center">25.4</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">94</td>
								<td align="center">20.5</td>
								<td align="center">5</td>
								<td align="center">10.2</td>
								<td align="center">89</td>
								<td align="center">21.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Condom use in the last sexual intercourse</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.383<sup>a</sup></td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">343</td>
								<td align="center">74.7</td>
								<td align="center">41</td>
								<td align="center">83.7</td>
								<td align="center">302</td>
								<td align="center">73.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">98</td>
								<td align="center">21.4</td>
								<td align="center">7</td>
								<td align="center">14.3</td>
								<td align="center">91</td>
								<td align="center">22.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">18</td>
								<td align="center">3.9</td>
								<td align="center">1</td>
								<td align="center">2.0</td>
								<td align="center">17</td>
								<td align="center">4.1</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Source of HIV infection exposure category</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.025<sup>a</sup></td>
							</tr>
							<tr>
								<td>Men (MSM)</td>
								<td align="center">234</td>
								<td align="center">51.0</td>
								<td align="center">34</td>
								<td align="center">69.4</td>
								<td align="center">200</td>
								<td align="center">48.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Men (non MSM)/women</td>
								<td align="center">168</td>
								<td align="center">36.6</td>
								<td align="center">12</td>
								<td align="center">24.5</td>
								<td align="center">156</td>
								<td align="center">38.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">57</td>
								<td align="center">12.4</td>
								<td align="center">3</td>
								<td align="center">6.1</td>
								<td align="center">54</td>
								<td align="center">13.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td align="center" colspan="8"><bold>Clinical</bold></td>
							</tr>
							<tr>
								<td>Clinical classification at the first visit</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.907<sup>a</sup></td>
							</tr>
							<tr>
								<td>Aids conditions (C)</td>
								<td align="center">96</td>
								<td align="center">20.9</td>
								<td align="center">11</td>
								<td align="center">22.4</td>
								<td align="center">85</td>
								<td align="center">20.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Asymptomatic (A)</td>
								<td align="center">291</td>
								<td align="center">63.4</td>
								<td align="center">30</td>
								<td align="center">61.2</td>
								<td align="center">261</td>
								<td align="center">63.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Symptomatic (B)</td>
								<td align="center">67</td>
								<td align="center">14.6</td>
								<td align="center">8</td>
								<td align="center">16.3</td>
								<td align="center">59</td>
								<td align="center">14.4</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">5</td>
								<td align="center">1.1</td>
								<td align="center">0</td>
								<td align="center">0.0</td>
								<td align="center">5</td>
								<td align="center">1.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Clinical classification at the last visit</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.351<sup>a</sup></td>
							</tr>
							<tr>
								<td>Aids conditions (C)</td>
								<td align="center">35</td>
								<td align="center">7.6</td>
								<td align="center">5</td>
								<td align="center">10.2</td>
								<td align="center">30</td>
								<td align="center">7.3</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Asymptomatic (A)</td>
								<td align="center">371</td>
								<td align="center">80.8</td>
								<td align="center">42</td>
								<td align="center">85.7</td>
								<td align="center">329</td>
								<td align="center">80.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Symptomatic (B)</td>
								<td align="center">16</td>
								<td align="center">3.5</td>
								<td align="center">0</td>
								<td align="center">0.0</td>
								<td align="center">16</td>
								<td align="center">3.9</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">37</td>
								<td align="center">8.1</td>
								<td align="center">2</td>
								<td align="center">4.1</td>
								<td align="center">35</td>
								<td align="center">8.5</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Comorbidities</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.951<sup>a</sup></td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">172</td>
								<td align="center">37.5</td>
								<td align="center">18</td>
								<td align="center">36.7</td>
								<td align="center">154</td>
								<td align="center">37.6</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">279</td>
								<td align="center">60.8</td>
								<td align="center">31</td>
								<td align="center">63.3</td>
								<td align="center">248</td>
								<td align="center">60.5</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">8</td>
								<td align="center">1.7</td>
								<td align="center">0</td>
								<td align="center">0.0</td>
								<td align="center">8</td>
								<td align="center">2.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Other STIs (except syphilis)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.021</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">41</td>
								<td align="center">8.9</td>
								<td align="center">9</td>
								<td align="center">18.4</td>
								<td align="center">32</td>
								<td align="center">7.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">418</td>
								<td align="center">91.1</td>
								<td align="center">40</td>
								<td align="center">81.6</td>
								<td align="center">378</td>
								<td align="center">92.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Mucosal lesions</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.086<sup>a</sup></td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">23</td>
								<td align="center">5.0</td>
								<td align="center">5</td>
								<td align="center">10.2</td>
								<td align="center">18</td>
								<td align="center">4.4</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">436</td>
								<td align="center">95.0</td>
								<td align="center">44</td>
								<td align="center">89.8</td>
								<td align="center">392</td>
								<td align="center">95.6</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>History of STI</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.204</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">134</td>
								<td align="center">29.2</td>
								<td align="center">16</td>
								<td align="center">32.7</td>
								<td align="center">118</td>
								<td align="center">28.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">124</td>
								<td align="center">27.0</td>
								<td align="center">9</td>
								<td align="center">18.4</td>
								<td align="center">115</td>
								<td align="center">28.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">201</td>
								<td align="center">43.8</td>
								<td align="center">24</td>
								<td align="center">49.0</td>
								<td align="center">177</td>
								<td align="center">43.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td align="center" colspan="8"><bold>Laboratory</bold></td>
							</tr>
							<tr>
								<td>Viral load at start of ART (copies/ml)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.812<sup>a</sup></td>
							</tr>
							<tr>
								<td>≤ 100 thousand</td>
								<td align="center">305</td>
								<td align="center">66.4</td>
								<td align="center">31</td>
								<td align="center">63.3</td>
								<td align="center">274</td>
								<td align="center">66.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>&gt; 100 thousand</td>
								<td align="center">114</td>
								<td align="center">24.8</td>
								<td align="center">14</td>
								<td align="center">28.6</td>
								<td align="center">100</td>
								<td align="center">24.4</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">40</td>
								<td align="center">8.7</td>
								<td align="center">4</td>
								<td align="center">8.2</td>
								<td align="center">36</td>
								<td align="center">8.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Viral load at start of ART</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.194<sup>a</sup></td>
							</tr>
							<tr>
								<td>Undetectable</td>
								<td align="center">11</td>
								<td align="center">2.4</td>
								<td align="center">3</td>
								<td align="center">6.1</td>
								<td align="center">8</td>
								<td align="center">2.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Detectable</td>
								<td align="center">408</td>
								<td align="center">88.9</td>
								<td align="center">42</td>
								<td align="center">85.7</td>
								<td align="center">366</td>
								<td align="center">89.3</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">40</td>
								<td align="center">8.7</td>
								<td align="center">4</td>
								<td align="center">8.2</td>
								<td align="center">36</td>
								<td align="center">8.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Viral load after 12 months of ART (copies/ml)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.211<sup>a</sup></td>
							</tr>
							<tr>
								<td>≤ 100 thousand</td>
								<td align="center">316</td>
								<td align="center">68.8</td>
								<td align="center">39</td>
								<td align="center">79.6</td>
								<td align="center">277</td>
								<td align="center">67.6</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>&gt; 100 thousand</td>
								<td align="center">3</td>
								<td align="center">0.7</td>
								<td align="center">0</td>
								<td align="center">0.0</td>
								<td align="center">3</td>
								<td align="center">0.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">140</td>
								<td align="center">30.5</td>
								<td align="center">10</td>
								<td align="center">20.4</td>
								<td align="center">130</td>
								<td align="center">31.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Viral load after 12 months of ART</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.203</td>
							</tr>
							<tr>
								<td>Undetectable</td>
								<td align="center">288</td>
								<td align="center">62.7</td>
								<td align="center">34</td>
								<td align="center">69.4</td>
								<td align="center">254</td>
								<td align="center">62.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Detectable</td>
								<td align="center">31</td>
								<td align="center">6.8</td>
								<td align="center">5</td>
								<td align="center">10.2</td>
								<td align="center">26</td>
								<td align="center">6.3</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">140</td>
								<td align="center">30.5</td>
								<td align="center">10</td>
								<td align="center">20.4</td>
								<td align="center">130</td>
								<td align="center">31.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>TCD4 lymphocytes at start of ART (cells/mm<sup>3</sup>)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.274<sup>a</sup></td>
							</tr>
							<tr>
								<td>&lt; 200</td>
								<td align="center">120</td>
								<td align="center">26.1</td>
								<td align="center">12</td>
								<td align="center">24.5</td>
								<td align="center">108</td>
								<td align="center">26.3</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>200–500</td>
								<td align="center">165</td>
								<td align="center">35.9</td>
								<td align="center">13</td>
								<td align="center">26.5</td>
								<td align="center">152</td>
								<td align="center">37.1</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>&gt; 500</td>
								<td align="center">134</td>
								<td align="center">29.2</td>
								<td align="center">20</td>
								<td align="center">40.8</td>
								<td align="center">114</td>
								<td align="center">27.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">40</td>
								<td align="center">8.7</td>
								<td align="center">4</td>
								<td align="center">8.2</td>
								<td align="center">36</td>
								<td align="center">8.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>TCD4 lymphocytes after 12 months of ART (cells/mm<sup>3</sup>)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.998</td>
							</tr>
							<tr>
								<td>&lt; 200</td>
								<td align="center">27</td>
								<td align="center">5.9</td>
								<td align="center">3</td>
								<td align="center">6.1</td>
								<td align="center">24</td>
								<td align="center">5.9</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>200–500</td>
								<td align="center">139</td>
								<td align="center">30.3</td>
								<td align="center">15</td>
								<td align="center">30.6</td>
								<td align="center">124</td>
								<td align="center">30.2</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>&gt; 500</td>
								<td align="center">155</td>
								<td align="center">33.8</td>
								<td align="center">16</td>
								<td align="center">32.7</td>
								<td align="center">139</td>
								<td align="center">33.9</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">138</td>
								<td align="center">30.1</td>
								<td align="center">15</td>
								<td align="center">30.6</td>
								<td align="center">123</td>
								<td align="center">30.0</td>
								<td>
								</td>
							</tr>
							<tr>
								<td align="center" colspan="8"><bold>Drug treatment</bold></td>
							</tr>
							<tr>
								<td>Mean time of HIV diagnosis (month)</td>
								<td align="center">15.3</td>
								<td align="center">SD = 32.1</td>
								<td align="center">8.5</td>
								<td align="center">SD = 13.4</td>
								<td align="center">16.1</td>
								<td align="center">SD = 33.5</td>
								<td align="center">0.004<sup>b</sup></td>
							</tr>
							<tr>
								<td>Time of HIV diagnosis (month)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.018<sup>a</sup></td>
							</tr>
							<tr>
								<td>≤ 3</td>
								<td align="center">131</td>
								<td align="center">28.5</td>
								<td align="center">21</td>
								<td align="center">42.9</td>
								<td align="center">110</td>
								<td align="center">26.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>&gt; 3</td>
								<td align="center">325</td>
								<td align="center">70.8</td>
								<td align="center">27</td>
								<td align="center">55.1</td>
								<td align="center">298</td>
								<td align="center">72.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">3</td>
								<td align="center">0.7</td>
								<td align="center">1</td>
								<td align="center">2.0</td>
								<td align="center">2</td>
								<td align="center">0.5</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Average time of ART treatment (days)</td>
								<td align="center">78.6</td>
								<td align="center">SD = 59.0</td>
								<td align="center">62.8</td>
								<td align="center">SD = 55.2</td>
								<td align="center">80.4</td>
								<td align="center">SD = 59.2</td>
								<td align="center">0.048<sup>b</sup></td>
							</tr>
							<tr>
								<td>Therapeutic regimen in use</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.085<sup>a</sup></td>
							</tr>
							<tr>
								<td>TLE</td>
								<td align="center">291</td>
								<td align="center">63.4</td>
								<td align="center">38</td>
								<td align="center">77.6</td>
								<td align="center">253</td>
								<td align="center">61.7</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>TLD</td>
								<td align="center">142</td>
								<td align="center">30.9</td>
								<td align="center">9</td>
								<td align="center">18.4</td>
								<td align="center">133</td>
								<td align="center">32.4</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Other regimens</td>
								<td align="center">26</td>
								<td align="center">5.7</td>
								<td align="center">2</td>
								<td align="center">4.1</td>
								<td align="center">24</td>
								<td align="center">5.9</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Non-adherence to ART in the last 15 days</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
								<td align="center">0.339</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">68</td>
								<td align="center">14.8</td>
								<td align="center">9</td>
								<td align="center">18.4</td>
								<td align="center">59</td>
								<td align="center">14.4</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">362</td>
								<td align="center">78.9</td>
								<td align="center">35</td>
								<td align="center">71.4</td>
								<td align="center">327</td>
								<td align="center">79.8</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Missing data</td>
								<td align="center">29</td>
								<td align="center">6.3</td>
								<td align="center">5</td>
								<td align="center">10.2</td>
								<td align="center">24</td>
								<td align="center">5.9</td>
								<td>
								</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TFN1">
							<p>PLHIV: people living with HIV; MSM: men who have sex with men; STI: sexually transmitted infections; TLE: tenofovir/lamivudine/efavirenz; TLD: tenofovir/lamivudine/dolutegravir; ART: antiretroviral therapy; SD: standard deviation.</p>
						</fn>
						<fn id="TFN2">
							<p><sup>a</sup> Fischer’s exact test.</p>
						</fn>
						<fn id="TFN3">
							<p><sup>b</sup> T-test for comparison of means.</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
			<p>We observed a 19.6% (n = 90) prevalence of STIs registered on the medical record, with more than half of the records being syphilis (n = 49). Among the 41 individuals diagnosed with STIs other than syphilis, we found 9.4% (n = 20) of condyloma and genital warts (anal, vaginal, perianal); 5.6% (n = 12) of genital herpes; 5.6% (n = 12) of hepatitis B and C; and 1.4% (n = 3) of other STIs (gonorrhea/trichomoniasis/unspecified STI). Other oral, anal or genital mucous lesions were also recorded (5%), described as penile lesion, erythematous itchy penis lesion, anal lesion, and genital lesion (data not shown in table).</p>
			<p>The prevalence of HIV/syphilis co-infected individuals in this study was 10.6% (n = 49). As for the clinical characteristics of these co-infected individuals, it was observed that most had unspecified syphilis (45%), followed by latent and late latent syphilis (26.6%), secondary (14.3%), tertiary (neurosyphilis and uveitis) (12.1%), and primary (primary genital) syphilis (2%). The mean time of the first syphilis episode after initiation of ART was 115.06 days (SD = 121.26), and the median was 53 days. The test reported in the registry was Venereal Disease Research Laboratory (VDRL), with 42.9% reagent results, and 55.1% had no test record. Penicillin G Benzathine was prescribed for 85.7% of the individuals being treated for syphilis, and 4.1% used other drugs such as doxycycline and ceftriaxone. We also observed 18.4% (n = 9) of other STIs, additionally to the co-infection, being these condyloma and genital warts, hepatitis B and C, and others (gonorrhea/trichomoniasis/unspecified STIs). It was also observed that 10.2% had some record of lesions in oral, anal or genital mucosa (data not shown in the table).</p>
			<p>As shown in <xref ref-type="table" rid="t1">Table 1</xref>, most co-infected individuals were male (93.9%), aged 20 to 34 years (53.1%), brown or black (71.5%), divorced/single/widowed (85.7%). As for behavioral characteristics, most were MSM (69.4%), had no fixed sexual partner (46.9%), and used alcohol in the month before the baseline interview (73.5%). As for condom use, 26.5% reported not having used in the last month, and 14.3% did not use in the last sexual intercourse. There were differences between the groups with and without co-infection for the variables sex (p = 0.018), formal education (p = 0.043), source of HIV infection (p = 0.025), diagnosis of other STIs (p = 0.021), mean time of HIV diagnosis (p = 0.004), and mean time of antiretroviral treatment (p = 0.048) (<xref ref-type="table" rid="t1">Table 1</xref>).</p>
			<p>The characteristics significantly associated with a higher chance of having HIV/syphilis co-infection in the bivariate analysis were male sex, being MSM, and having a diagnosis of other STIs. The characteristics associated with a lower chance of HIV/syphilis co-infection were longer duration of ART, and use of the TLD antiretroviral regimen (<xref ref-type="table" rid="t2">Table 2</xref>).</p>
			<p>
				<table-wrap id="t2">
					<label>Table 2</label>
					<caption>
						<title>Bivariate analysis of factors associated with HIV/syphilis coinfection, Belo Horizonte, Minas Gerais, 2015–2018 (n = 459).</title>
					</caption>
					<table frame="hsides" rules="groups">
						<colgroup>
							<col/>
							<col/>
							<col/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left">Characteristics</th>
								<th>n (%)<sup>a</sup></th>
								<th>OR (95%CI)</th>
								<th>p</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td align="center" colspan="4"><bold>Sociodemographic</bold></td>
							</tr>
							<tr>
								<td>Sex</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Male</td>
								<td align="center">374 (81.5)</td>
								<td align="center">3.83 (1.16–12.64)</td>
								<td align="center">0.027</td>
							</tr>
							<tr>
								<td>Female</td>
								<td align="center">85 (18.5)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Age (years)</td>
								<td align="center">459 (100)</td>
								<td align="center">1.01 (0.98–1.03)</td>
								<td align="center">0.674</td>
							</tr>
							<tr>
								<td>Color/ethnicity</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Brown/black</td>
								<td align="center">328 (72.2)</td>
								<td align="center">0.96 (0.50–1.84)</td>
								<td align="center">0.892</td>
							</tr>
							<tr>
								<td>White/yellow/indigenous</td>
								<td align="center">126 (27.8)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Marital status</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Single/divorced/widowed</td>
								<td align="center">366 (79.7)</td>
								<td align="center">1.59 (0.69–3.67)</td>
								<td align="center">0.275</td>
							</tr>
							<tr>
								<td>Married/commonwealth marriage</td>
								<td align="center">93 (20.3)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Children</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">162 (35.3)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">297 (64.7)</td>
								<td align="center">1.41 (0.74–2.71)</td>
								<td align="center">0.299</td>
							</tr>
							<tr>
								<td>Formal education (years)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>≤ 9</td>
								<td align="center">117 (25.5)</td>
								<td align="center">0.83 (0.41–1.68)</td>
								<td align="center">0.599</td>
							</tr>
							<tr>
								<td>≥ 10</td>
								<td align="center">341 (74.5)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Job</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">269 (58.6)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">190 (41.4)</td>
								<td align="center">0.89 (0.48–1.63)</td>
								<td align="center">0.694</td>
							</tr>
							<tr>
								<td>Own income</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">373 (81.4)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">85 (18.6)</td>
								<td align="center">0.73 (0.31–1.68)</td>
								<td align="center">0.456</td>
							</tr>
							<tr>
								<td>Economic class</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>High (A-B)</td>
								<td align="center">162 (36.2)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Intermediate-low (C-D-E)</td>
								<td align="center">285 (63.8)</td>
								<td align="center">0.74 (0.40–1.37)</td>
								<td align="center">0.343</td>
							</tr>
							<tr>
								<td>Private health plan</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">121 (26.4)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">338 (73.6)</td>
								<td align="center">1.27 (0.63–2.57)</td>
								<td align="center">0.511</td>
							</tr>
							<tr>
								<td>Place of residence</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Metropolitan region/other municipalities</td>
								<td align="center">55 (12.0)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Belo Horizonte</td>
								<td align="center">404 (88.0)</td>
								<td align="center">1.22 (0.46–3.23)</td>
								<td align="center">0.685</td>
							</tr>
							<tr>
								<td align="center" colspan="4"><bold>Behavioral and life habits</bold></td>
							</tr>
							<tr>
								<td>Fixed sexual partner within 12 months after ART</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">218 (47.5)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">187 (40.7)</td>
								<td align="center">1.25 (0.67–2.32)</td>
								<td align="center">0.482</td>
							</tr>
							<tr>
								<td>Use of alcohol in the month before the interview</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">294 (64.5)</td>
								<td align="center">1.60 (0.82–3.11)</td>
								<td align="center">0.167</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">162 (35.5)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Current use of tobacco</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">126 (27.5)</td>
								<td align="center">1.19 (0.62–2.27)</td>
								<td align="center">0.600</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">333 (72.5)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Use of illicit drugs in life ever</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">221 (48.4)</td>
								<td align="center">1.35 (0.75–2.46)</td>
								<td align="center">0.319</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">236 (51.6)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Condom use in the last month</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">248 (67.9)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">117 (32.1)</td>
								<td align="center">0.88 (0.44–1.74)</td>
								<td align="center">0.704</td>
							</tr>
							<tr>
								<td>Condom use in the last sexual intercourse</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">343 (77.8)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">98 (22.2)</td>
								<td align="center">0.57 (0.25–1.31)</td>
								<td align="center">0.182</td>
							</tr>
							<tr>
								<td>Source of HIV infection - exposure category</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Men (MSM)</td>
								<td align="center">234 (51.0)</td>
								<td align="center">2.21 (1.11–4.41)</td>
								<td align="center">0.024</td>
							</tr>
							<tr>
								<td>Men (non MSM)/women</td>
								<td align="center">168 (36.6)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td align="center" colspan="4"><bold>Clinical</bold></td>
							</tr>
							<tr>
								<td>Clinical classification at the first visit</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Aids conditions (C)</td>
								<td align="center">96 (21.1)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No Aids (A-B)</td>
								<td align="center">358 (78.9)</td>
								<td align="center">1.09 (0.54–2.22)</td>
								<td align="center">0.813</td>
							</tr>
							<tr>
								<td>Clinical classification at the last visit</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Aids conditions (C)</td>
								<td align="center">35 (8.3)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>No Aids (A-B)</td>
								<td align="center">387 (91.7)</td>
								<td align="center">0.73 (0.27–1.98)</td>
								<td align="center">0.538</td>
							</tr>
							<tr>
								<td>Comorbidities</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">172 (38.1)</td>
								<td align="center">0.94 (0.51–1.73)</td>
								<td align="center">0.830</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">279 (61.9)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Other STIs (except syphilis)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">41 (8.9)</td>
								<td align="center">2.66 (1.19–5.96)</td>
								<td align="center">0.018</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">418 (91.1)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Mucosal lesions</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">23 (5.0)</td>
								<td align="center">2.48 (0.88–6.99)</td>
								<td align="center">0.087</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">436 (95.0)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td align="center" colspan="4"><bold>Laboratory</bold></td>
							</tr>
							<tr>
								<td>Viral load at start of ART</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Detectable</td>
								<td align="center">408 (88.9)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Undetectable</td>
								<td align="center">11 (2.4)</td>
								<td align="center">3.27 (0.84–12.79)</td>
								<td align="center">0.089</td>
							</tr>
							<tr>
								<td>Viral load after 12 months of ART</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Detectable</td>
								<td align="center">31 (6.8)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Undetectable</td>
								<td align="center">288 (62.7)</td>
								<td align="center">0.70 (0.25–1.93)</td>
								<td align="center">0.487</td>
							</tr>
							<tr>
								<td>TCD4 lymphocytes at start of ART (cells/mm<sup>3</sup>)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>&lt; 200</td>
								<td align="center">120 (26.1)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>200–500</td>
								<td align="center">165 (35.9)</td>
								<td align="center">0.77 (0.34–1.75)</td>
								<td align="center">0.533</td>
							</tr>
							<tr>
								<td>&gt; 500</td>
								<td align="center">134 (29.2)</td>
								<td align="center">1.58 (0.74–3.39)</td>
								<td align="center">0.240</td>
							</tr>
							<tr>
								<td>TCD4 lymphocytes after 12 months of ART (cells/mm<sup>3</sup>)</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>&lt; 200</td>
								<td align="center">27 (5.9)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>200–500</td>
								<td align="center">139 (30.3)</td>
								<td align="center">0.97 (0.26–3.60)</td>
								<td align="center">0.961</td>
							</tr>
							<tr>
								<td>&gt; 500</td>
								<td align="center">155 (33.8)</td>
								<td align="center">0.92 (0.25–3.40)</td>
								<td align="center">0.902</td>
							</tr>
							<tr>
								<td align="center" colspan="4"><bold>Drug treatment</bold></td>
							</tr>
							<tr>
								<td>Time of HIV diagnosis (months)</td>
								<td align="center">456 (100.0)</td>
								<td align="center">0.99 (0.97–1.01)</td>
								<td align="center">0.138</td>
							</tr>
							<tr>
								<td>Average time of antiretroviral treatment (days)</td>
								<td align="center">459 (100.0)</td>
								<td align="center">0.99 (0.99–1.00)</td>
								<td align="center">0.050</td>
							</tr>
							<tr>
								<td>Therapeutic regimen in use</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>TLE</td>
								<td align="center">291 (63.4)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>TLD</td>
								<td align="center">142 (30.9)</td>
								<td align="center">0.45 (0.21–0.96)</td>
								<td align="center">0.039</td>
							</tr>
							<tr>
								<td>Other regimens</td>
								<td align="center">26 (5.7)</td>
								<td align="center">0.56 (0.13–2.44)</td>
								<td align="center">0.436</td>
							</tr>
							<tr>
								<td>Self-report of non-adherence to ART in the last 15 days</td>
								<td>
								</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">68 (15.8)</td>
								<td align="center">1.43 (0.65–3.12)</td>
								<td align="center">0.375</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">362 (84.2)</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TFN4">
							<p>OR: odds ratio; 95%CI: 95% confidence interval; ART: antiretroviral therapy; MSM: men who have sex with men; STI: sexually transmitted infections; TLE: Tenofovir/Lamivudine/Efavirenz; TLD: Tenofovir/Lamivudine/Dolutegravir.</p>
						</fn>
						<fn id="TFN5">
							<p><sup>a</sup> Numbers vary as data are ignored.</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
			<p>In the multivariate analysis (<xref ref-type="table" rid="t3">Table 3</xref>), the independent characteristics associated with a higher chance of co-infection were having been diagnosed with other STIs (OR = 3.33; 95%CI: 1.24–8.95), and alcohol use in the month before the interview (OR = 2.30; 95%CI: 1.01–5.26). The variables sex and length of antiretroviral treatment remained in the final model, but did not report statistical significance.</p>
			<p>
				<table-wrap id="t3">
					<label>Table 3</label>
					<caption>
						<title>Multiple logistic regression of factors associated with HIV/syphilis co-infection, Belo Horizonte, Minas Gerais, 2015–2018 (n = 349a).</title>
					</caption>
					<table frame="hsides" rules="groups">
						<colgroup>
							<col/>
							<col/>
							<col/>
						</colgroup>
						<thead>
							<tr>
								<th align="left">Characteristics</th>
								<th>OR (95%CI)</th>
								<th>p</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>Sex</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Male</td>
								<td align="center">3.58 (0.82–15.58)</td>
								<td align="center">0.089</td>
							</tr>
							<tr>
								<td>Female</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Use of alcohol in the month before the interview</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">2.30 (1.01–5.26)</td>
								<td align="center">0.049</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Diagnosis of other STIs (except syphilis)</td>
								<td>
								</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Yes</td>
								<td align="center">3.33 (1.24–8.95)</td>
								<td align="center">0.017</td>
							</tr>
							<tr>
								<td>No</td>
								<td align="center">1.00</td>
								<td>
								</td>
							</tr>
							<tr>
								<td>Average time of antiretroviral treatment (days)</td>
								<td align="center">0.99 (0.99–1.00)</td>
								<td align="center">0.066</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TFN6">
							<p>OR: odds ratio; 95%CI: 95% confidence interval. STI: sexually transmitted infections; ROC: Receiver Operating Characteristics.</p>
						</fn>
						<fn id="TFN7">
							<p><sup>a</sup> 110 patients with missing data in covariates were excluded from the final model.</p>
						</fn>
						<fn id="TFN8">
							<p>Model fit: Hosmer and Lemeshow test: X2 = 7.66; df = 8; p-value = 0.468; area under the ROC curve = 0.688.</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
		</sec>
		<sec sec-type="discussion">
			<title>DISCUSSION</title>
			<p>People living with HIV (PLHIV) seen in three public specialized HIV care services in Belo Horizonte, who were starting ART, showed high prevalence of STI co-infection (19.6%), with syphilis (10.6%) being the most prevalent. It is noteworthy that the estimated overall prevalence of syphilis among men and women without HIV infection is 0.5% in Brazil<sup><xref ref-type="bibr" rid="B1">1</xref></sup>. Characteristics independently associated with HIV/syphilis co-infection were diagnosis of other STIs, and use of alcohol in the month prior to the interview.</p>
			<p>The prevalence and factors associated with syphilis in PLHIV vary both in Brazilian and international studies. This variation depends on the type of population, such as the key population (transgender, sex workers, people who inject drugs, MSM, and prisoners - and their partners) that have higher prevalence of HIV/syphilis co-infection<sup><xref ref-type="bibr" rid="B14">14</xref></sup>.</p>
			<p>The prevalence of HIV/syphilis co-infection observed in this study was lower than that found in a study conducted in Mkushi, Zambia, in which the authors observed 40.5% HIV/syphilis co-infection in newly diagnosed HIV-positive individuals starting ART<sup><xref ref-type="bibr" rid="B15">15</xref></sup>. It was also lower than the prevalence found in a prospective multicenter study of MSM in Germany, which was 39.6%<sup><xref ref-type="bibr" rid="B16">16</xref></sup>. In another study conducted in Brazil with sex workers, the prevalence was 30.8%<sup><xref ref-type="bibr" rid="B17">17</xref></sup>.</p>
			<p>Similar to other studies<sup><xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref></sup>, we also found that having been diagnosed with other STIs was independently associated with a higher chance of HIV/syphilis co-infection. This result may indicate that risky sexual behavior among PLHIV may contribute to the spread of HIV infection, and affect the transmission control.</p>
			<p>The STIs are transmitted by sexual contact without the use of condoms, an important preventive measure among HIV serodiscordant and seroconcordant couples to prevent the transmission of other STIs. One study found the presence of syphilis, cytomegalovirus, human papillomavirus (HPV), and herpes simplex virus in MSM living with HIV<sup><xref ref-type="bibr" rid="B20">20</xref></sup>. Similarly, in our study we found the presence of condylomata and genital warts, genital herpes, hepatitis B and C and others (gonorrhea/trichomoniasis/unspecified STDs), besides lesions in anal and genital mucosa.</p>
			<p>PLHIV are at higher risk of co-infection with hepatitis and syphilis than the population at large. Bacterial infections, protozoa, genital herpes, and previous sexual infections have been described as risk factors for HIV/syphilis co-infection. STIs may indicate risky sexual behavior among PLHIV, increasing the possibility of HIV infection and affecting the control of transmission<sup><xref ref-type="bibr" rid="B20">20</xref></sup><sub>.</sub></p>
			<p>Another study reviewed the factors associated with HIV/STI co-infection in 295 PLHIV, in which 37% had at least one STI. Among the STIs cited, 32% were syphilis, 16% gonorrhea, and 8% chlamydia. The high prevalence of STIs among PLHIV suggests the need for adequate testing, prevention, and treatment among this population<sup><xref ref-type="bibr" rid="B21">21</xref></sup>.</p>
			<p>In this study, reports of alcohol use prior to the interview were associated with a higher chance of HIV/syphilis co-infection, a result similar to other studies<sup><xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref></sup>. Alcohol consumption is a serious public health problem since it may lead individuals to adopt risky sexual practices and contribute to the lack of STI preventive habits, such as not using condoms, changing partners frequently, and engaging in group or anal sex, leading to increased chances of contracting syphilis and other STIs. This scenario contributes to maintaining the chain of transmission of STIs among PLHIV<sup><xref ref-type="bibr" rid="B24">24</xref></sup><sub>.</sub></p>
			<p>Alcohol is a substance that depresses the central nervous system, and reduces anxiety and inhibition. The belief that using alcohol increases pleasure causes it to be used before or during sexual practices. It is estimated that alcohol consumption among PLHIV is 2.5 times higher than in the remaining population. The use of alcohol and drugs increases up to six times the risk of people with HIV to have unprotected sex and multiple partners. In one study, the prevalence of alcohol abuse among people living with HIV was estimated at 28.6%<sup><xref ref-type="bibr" rid="B25">25</xref></sup><sub>.</sub></p>
			<p>Longer duration of ART was associated with lower chance of HIV/syphilis co-infection, and remained in the final model due to greater robustness, although it did not show statistical significance. It is noteworthy that the results of studies evaluating the association between ART use and STI transmission are controversial.</p>
			<p>A retrospective cohort study found an association between the use of ART and a lower chance of HIV/syphilis co-infection at the beginning of treatment, supporting the results found in this study. On the other hand, ART use was associated with higher chance of co-infection in individuals who had syphilis seroconversion during follow-up<sup><xref ref-type="bibr" rid="B26">26</xref></sup>. In a study by Tsachouridou et al.<sup><xref ref-type="bibr" rid="B27">27</xref></sup>, individuals taking ART were 2.4 times more likely to have HIV/syphilis co-infection. These studies indicate that the advantages of antiretroviral use are reflected in the sexual behavior of PLHIV of not using condoms. It is likely to be so because feel safe about not transmitting the HIV virus<sup><xref ref-type="bibr" rid="B27">27</xref></sup>.</p>
			<p>In our study, the male sex variable was associated with lower chance of HIV/syphilis co-infection, and remained in the final model due to greater robustness, although it did not show statistical significance. This result was consistent with that of other studies that showed a higher risk of co-infection among males<sup><xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref></sup>.</p>
			<p>The prevalence of syphilis and the different STIs found in this study may reflect the inconsistent use of condoms, and other actions to prevent these infections. Awareness about the factors associated with the prevalence of HIV/syphilis co-infection may support the decision-making of professionals involved in the care of PLHIV. The follow-up and adequate treatment of syphilis and STIs require guidance on safe sex practices to prevent these co-infections among the PLHIV.</p>
			<p>The limitations of the study concern the use of secondary data with missing elements of general records on clinical information, and laboratory tests of individuals.</p>
			<p>The strengths of this study are the quality and processing of primary data collected, with reliability analysis of 10% of the total sample for collection and entry. Of note is the high perfect interdigitated agreement assessed by Kappa statistics, the comprehensive inclusion of explanatory variables, and the robustness of the final model.</p>
			<p>The conclusion is that the prevalence of STIs recorded was high, and syphilis was the most prevalent co-infection. Alcohol use and diagnosis of other STIs were associated with a higher chance of HIV/syphilis co-infection among this population.</p>
		</sec>
	</body>
	<back>
		<ref-list>
			<title>REFERENCES</title>
			<ref id="B1">
				<label>1</label>
				<mixed-citation>1. World Health Organization. Report on global sexually transmitted infection surveillance, 2018. Geneva (CH): WHO; 2018 [cited 2021 May 25]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/reproductivehealth/publications/stis-surveillance-2018/en/">https://www.who.int/reproductivehealth/publications/stis-surveillance-2018/en/</ext-link>
				</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>World Health Organization</collab>
					</person-group>
					<source>Report on global sexually transmitted infection surveillance, 2018</source>
					<publisher-loc>Geneva (CH)</publisher-loc>
					<publisher-name>WHO</publisher-name>
					<year>2018</year>
					<date-in-citation content-type="cited-date">cited 2021 May 25</date-in-citation>
					<ext-link ext-link-type="uri" xlink:href="https://www.who.int/reproductivehealth/publications/stis-surveillance-2018/en/">https://www.who.int/reproductivehealth/publications/stis-surveillance-2018/en/</ext-link>
				</element-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation>2. Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis (IST). Brasília, DF; 2020 [cited 2021 May 25]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.aids.gov.br/pt-br/pub/2015/protocolo-clinico-e-diretrizes-terapeuticas-para-atencao-integral-pessoas-com-infeccoes">http://www.aids.gov.br/pt-br/pub/2015/protocolo-clinico-e-diretrizes-terapeuticas-para-atencao-integral-pessoas-com-infeccoes</ext-link>
				</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>Ministério da Saúde (BR)</collab>
						<collab>Secretaria de Vigilância em Saúde</collab>
						<collab>Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis</collab>
					</person-group>
					<source>Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis (IST)</source>
					<publisher-loc>Brasília, DF</publisher-loc>
					<year>2020</year>
					<date-in-citation content-type="cited-date">cited 2021 May 25</date-in-citation>
					<ext-link ext-link-type="uri" xlink:href="http://www.aids.gov.br/pt-br/pub/2015/protocolo-clinico-e-diretrizes-terapeuticas-para-atencao-integral-pessoas-com-infeccoes">http://www.aids.gov.br/pt-br/pub/2015/protocolo-clinico-e-diretrizes-terapeuticas-para-atencao-integral-pessoas-com-infeccoes</ext-link>
				</element-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation>3. Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Bol Epidemiol Sífilis. 2020;Nº Espec. [cited 2021 May 25]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.aids.gov.br/pt-br/pub/2020/boletim-sifilis-2020">http://www.aids.gov.br/pt-br/pub/2020/boletim-sifilis-2020</ext-link>
				</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>Ministério da Saúde (BR)</collab>
						<collab>Secretaria de Vigilância em Saúde</collab>
						<collab>Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis</collab>
					</person-group>
					<source>Bol Epidemiol Sífilis</source>
					<year>2020</year>
					<issue>Espec</issue>
					<date-in-citation content-type="cited-date">cited 2021 May 25</date-in-citation>
					<ext-link ext-link-type="uri" xlink:href="http://www.aids.gov.br/pt-br/pub/2020/boletim-sifilis-2020">http://www.aids.gov.br/pt-br/pub/2020/boletim-sifilis-2020</ext-link>
				</element-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation>4. Mora Y, Mago H, Díaz I. Coinfección VIH-sífilis en pacientes con diagnóstico reciente de infección por virus de inmunodeficiencia humana, octubre 2018 - mayo 2019, Unidad de Infectología. Ciudad Hospitalaria Dr. Enrique Tejera. Bol Venez Infectol. 2019 [cited 2021 May 25];30(2):116-21. Available from: <ext-link ext-link-type="uri" xlink:href="https://docs.bvsalud.org/biblioref/2019/11/1024096/05-mora-y-116-121.pdf">https://docs.bvsalud.org/biblioref/2019/11/1024096/05-mora-y-116-121.pdf</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mora</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Mago</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Díaz</surname>
							<given-names>I</given-names>
						</name>
					</person-group>
					<article-title>Coinfección VIH-sífilis en pacientes con diagnóstico reciente de infección por virus de inmunodeficiencia humana, octubre 2018 - mayo 2019, Unidad de Infectología. Ciudad Hospitalaria Dr. Enrique Tejera</article-title>
					<source>Bol Venez Infectol</source>
					<year>2019</year>
					<date-in-citation content-type="cited-date">cited 2021 May 25</date-in-citation>
					<volume>30</volume>
					<issue>2</issue>
					<fpage>116</fpage>
					<lpage>121</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://docs.bvsalud.org/biblioref/2019/11/1024096/05-mora-y-116-121.pdf">https://docs.bvsalud.org/biblioref/2019/11/1024096/05-mora-y-116-121.pdf</ext-link>
				</element-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation>5. Santos OP, Souza MR, Borges CJ, Noll M, Lima FC, Barros PS. Hepatites B, C e sífilis: prevalência e características associadas à coinfecção entre soropositivos. Cogitare Enferm. 2017;22(3):e51693.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Santos</surname>
							<given-names>OP</given-names>
						</name>
						<name>
							<surname>Souza</surname>
							<given-names>MR</given-names>
						</name>
						<name>
							<surname>Borges</surname>
							<given-names>CJ</given-names>
						</name>
						<name>
							<surname>Noll</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Lima</surname>
							<given-names>FC</given-names>
						</name>
						<name>
							<surname>Barros</surname>
							<given-names>PS</given-names>
						</name>
					</person-group>
					<article-title>Hepatites B, C e sífilis: prevalência e características associadas à coinfecção entre soropositivos</article-title>
					<source>Cogitare Enferm</source>
					<year>2017</year>
					<volume>22</volume>
					<issue>3</issue>
					<elocation-id>e51693</elocation-id>
				</element-citation>
			</ref>
			<ref id="B6">
				<label>6</label>
				<mixed-citation>6. Luppi CG, Gomes SEC, Silva RJC, Ueno AM, Santos AMK, Tayra A, et al. Fatores associados à coinfecção por HIV em casos de sífilis adquirida notificados em um Centro de Referência de Doenças Sexualmente Transmissíveis e Aids no município de São Paulo, 2014. Epidemiol. Serv. Saúde. 2018;27(1):e20171678. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5123/s1679-49742018000100008">https://doi.org/10.5123/s1679-49742018000100008</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Luppi</surname>
							<given-names>CG</given-names>
						</name>
						<name>
							<surname>Gomes</surname>
							<given-names>SEC</given-names>
						</name>
						<name>
							<surname>Silva</surname>
							<given-names>RJC</given-names>
						</name>
						<name>
							<surname>Ueno</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>Santos</surname>
							<given-names>AMK</given-names>
						</name>
						<name>
							<surname>Tayra</surname>
							<given-names>A</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Fatores associados à coinfecção por HIV em casos de sífilis adquirida notificados em um Centro de Referência de Doenças Sexualmente Transmissíveis e Aids no município de São Paulo, 2014</article-title>
					<source>Epidemiol. Serv. Saúde</source>
					<year>2018</year>
					<volume>27</volume>
					<issue>1</issue>
					<elocation-id>e20171678</elocation-id>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5123/s1679-49742018000100008">https://doi.org/10.5123/s1679-49742018000100008</ext-link>
				</element-citation>
			</ref>
			<ref id="B7">
				<label>7</label>
				<mixed-citation>7. Ferreira-Júnior OC, Guimarães MDC, Damacena GN, Almeida WS, Souza-Júnior PRB, Szwarcwald CL; Brazilian FSW Group. Prevalence estimates of HIV, syphilis, hepatitis B and C among female sex workers (FSW) in Brazil, 2016. Medicine (Baltimore). 2018;97(1Suppl):S3-8. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MD.0000000000009218">https://doi.org/10.1097/MD.0000000000009218</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ferreira-Júnior</surname>
							<given-names>OC</given-names>
						</name>
						<name>
							<surname>Guimarães</surname>
							<given-names>MDC</given-names>
						</name>
						<name>
							<surname>Damacena</surname>
							<given-names>GN</given-names>
						</name>
						<name>
							<surname>Almeida</surname>
							<given-names>WS</given-names>
						</name>
						<name>
							<surname>Souza-Júnior</surname>
							<given-names>PRB</given-names>
						</name>
						<name>
							<surname>Szwarcwald</surname>
							<given-names>CL</given-names>
						</name>
						<collab>Brazilian FSW Group</collab>
					</person-group>
					<article-title>Prevalence estimates of HIV, syphilis, hepatitis B and C among female sex workers (FSW) in Brazil, 2016</article-title>
					<source>Medicine (Baltimore)</source>
					<year>2018</year>
					<volume>97</volume>
					<supplement>1Suppl</supplement>
					<fpage>S3</fpage>
					<lpage>S8</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MD.0000000000009218">https://doi.org/10.1097/MD.0000000000009218</ext-link>
				</element-citation>
			</ref>
			<ref id="B8">
				<label>8</label>
				<mixed-citation>8. Amorim LT, Schlemper Jr BR. HIV/AIDS in small cities in Midwest Santa Catarina, south of Brazil: clinical and epidemiological aspects, opportunistic infections. Rev Soc Bras Med Trop. 2019;52:e20180430. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/0037-8682-0430-2018">https://doi.org/10.1590/0037-8682-0430-2018</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Amorim</surname>
							<given-names>LT</given-names>
						</name>
						<name>
							<surname>Schlemper</surname>
							<given-names>BR</given-names>
							<suffix>Jr</suffix>
						</name>
					</person-group>
					<article-title>HIV/AIDS in small cities in Midwest Santa Catarina, south of Brazil: clinical and epidemiological aspects, opportunistic infections</article-title>
					<source>Rev Soc Bras Med Trop</source>
					<year>2019</year>
					<volume>52</volume>
					<elocation-id>e20180430</elocation-id>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/0037-8682-0430-2018">https://doi.org/10.1590/0037-8682-0430-2018</ext-link>
				</element-citation>
			</ref>
			<ref id="B9">
				<label>9</label>
				<mixed-citation>9. Silva BEB, Santos VS, Santos IER, Batista MVA, Gonçalves LLC, Lemos LMD. Prevalence of co-infections in women living with human immunodeficiency virus in Northeast Brazil. Rev Soc Bras Med Trop. 2020;53:e20190282. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/0037-8682-0282-2019">https://doi.org/10.1590/0037-8682-0282-2019</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Silva</surname>
							<given-names>BEB</given-names>
						</name>
						<name>
							<surname>Santos</surname>
							<given-names>VS</given-names>
						</name>
						<name>
							<surname>Santos</surname>
							<given-names>IER</given-names>
						</name>
						<name>
							<surname>Batista</surname>
							<given-names>MVA</given-names>
						</name>
						<name>
							<surname>Gonçalves</surname>
							<given-names>LLC</given-names>
						</name>
						<name>
							<surname>Lemos</surname>
							<given-names>LMD</given-names>
						</name>
					</person-group>
					<article-title>Prevalence of co-infections in women living with human immunodeficiency virus in Northeast Brazil</article-title>
					<source>Rev Soc Bras Med Trop</source>
					<year>2020</year>
					<volume>53</volume>
					<elocation-id>e20190282</elocation-id>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/0037-8682-0282-2019">https://doi.org/10.1590/0037-8682-0282-2019</ext-link>
				</element-citation>
			</ref>
			<ref id="B10">
				<label>10</label>
				<mixed-citation>10. Weng RX, Hong FC, Yu WY, Cai YM. Compare HIV/syphilis infections between age groups and explore associated factors of HIV/syphilis co-infections among men who have sex with men in Shenzhen, China, from 2009 to 2017. PLoS One. 2019;14(10):e0223377. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0223377">https://doi.org/10.1371/journal.pone.0223377</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Weng</surname>
							<given-names>RX</given-names>
						</name>
						<name>
							<surname>Hong</surname>
							<given-names>FC</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>WY</given-names>
						</name>
						<name>
							<surname>Cai</surname>
							<given-names>YM</given-names>
						</name>
					</person-group>
					<article-title>Compare HIV/syphilis infections between age groups and explore associated factors of HIV/syphilis co-infections among men who have sex with men in Shenzhen, China, from 2009 to 2017</article-title>
					<source>PLoS One</source>
					<year>2019</year>
					<volume>14</volume>
					<issue>10</issue>
					<fpage>e0223377</fpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0223377">https://doi.org/10.1371/journal.pone.0223377</ext-link>
				</element-citation>
			</ref>
			<ref id="B11">
				<label>11</label>
				<mixed-citation>11. Liu Y, Tang HF, Ning Z, Zheng H, He N, Zhang YY. [Co-infections of HIV, syphilis and HSV-2 among men who have sex with men at the voluntary HIV counseling and testing clinics in Shanghai]. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38(10):1363-6. Chinese. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3760/cma.j.issn.0254-6450.2017.10.013">https://doi.org/10.3760/cma.j.issn.0254-6450.2017.10.013</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Liu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Tang</surname>
							<given-names>HF</given-names>
						</name>
						<name>
							<surname>Ning</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Zheng</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>He</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>YY</given-names>
						</name>
					</person-group>
					<article-title>Co-infections of HIV, syphilis and HSV-2 among men who have sex with men at the voluntary HIV counseling and testing clinics in Shanghai</article-title>
					<source>Zhonghua Liu Xing Bing Xue Za Zhi</source>
					<year>2017</year>
					<volume>38</volume>
					<issue>10</issue>
					<fpage>1363</fpage>
					<lpage>1366</lpage>
					<comment>Chinese</comment>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3760/cma.j.issn.0254-6450.2017.10.013">https://doi.org/10.3760/cma.j.issn.0254-6450.2017.10.013</ext-link>
				</element-citation>
			</ref>
			<ref id="B12">
				<label>12</label>
				<mixed-citation>12. Mutagoma M, Nyirazinyoye L, Sebuhoro D, Riedel DJ, Ntaganira J. Syphilis and HIV prevalence and associated factors to their co-infection, hepatitis B and hepatitis C viruses prevalence among female sex workers in Rwanda. BMC Infect Dis. 2017;17(1):525. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12879-017-2625-0">https://doi.org/10.1186/s12879-017-2625-0</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mutagoma</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Nyirazinyoye</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Sebuhoro</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Riedel</surname>
							<given-names>DJ</given-names>
						</name>
						<name>
							<surname>Ntaganira</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Syphilis and HIV prevalence and associated factors to their co-infection, hepatitis B and hepatitis C viruses prevalence among female sex workers in Rwanda</article-title>
					<source>BMC Infect Dis</source>
					<year>2017</year>
					<volume>17</volume>
					<issue>1</issue>
					<size units="pages">525</size>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12879-017-2625-0">https://doi.org/10.1186/s12879-017-2625-0</ext-link>
				</element-citation>
			</ref>
			<ref id="B13">
				<label>13</label>
				<mixed-citation>13. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19 [cited 2021 May 25]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm">https://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm</ext-link>
				</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>Centers for Disease Control and Prevention</collab>
					</person-group>
					<article-title>1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults</article-title>
					<source>MMWR Recomm Rep</source>
					<year>1992</year>
					<volume>41</volume>
					<issue>RR-17</issue>
					<fpage>1</fpage>
					<lpage>19</lpage>
					<date-in-citation content-type="cited-date">cited 2021 May 25</date-in-citation>
					<ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm">https://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm</ext-link>
				</element-citation>
			</ref>
			<ref id="B14">
				<label>14</label>
				<mixed-citation>14. Joint United Nations Programme on HIV/AIDS. Global AIDS update 2020 Geneva (CH): UNAIDS; 2020 [cited 2021 Dec 1]. Available from: <ext-link ext-link-type="uri" xlink:href="https://unaids.org.br/estatisticas/">https://unaids.org.br/estatisticas/</ext-link>
				</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>Joint United Nations Programme on HIV/AIDS</collab>
					</person-group>
					<source>Global AIDS update 2020</source>
					<publisher-loc>Geneva (CH)</publisher-loc>
					<publisher-name>UNAIDS</publisher-name>
					<year>2020</year>
					<date-in-citation content-type="cited-date">cited 2021 Dec 1</date-in-citation>
					<ext-link ext-link-type="uri" xlink:href="https://unaids.org.br/estatisticas/">https://unaids.org.br/estatisticas/</ext-link>
				</element-citation>
			</ref>
			<ref id="B15">
				<label>15</label>
				<mixed-citation>15. Katamba C, Chungu T, Lusale C. HIV, syphilis, and hepatitis B co-infections in Mkushi, Zambia: a cross-sectional study. F1000 Res. 2019;8:562. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.12688/f1000research.17983.2">https://doi.org/10.12688/f1000research.17983.2</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Katamba</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Chungu</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Lusale</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>HIV, syphilis, and hepatitis B co-infections in Mkushi, Zambia: a cross-sectional study</article-title>
					<source>F1000 Res</source>
					<year>2019</year>
					<volume>8</volume>
					<size units="pages">562</size>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.12688/f1000research.17983.2">https://doi.org/10.12688/f1000research.17983.2</ext-link>
				</element-citation>
			</ref>
			<ref id="B16">
				<label>16</label>
				<mixed-citation>16. Jansen K, Thamm M, Bock CT, Scheufele R, Kücherer C, Muenstermann D, et al. High prevalence and high incidence of co-infection with hepatitis B, hepatitis C, and syphilis and low rate of effective vaccination against hepatitis B in HIV-positive men who have sex with men with known date of HIV seroconversion in Germany. PLoS One. 2015;10(11):e0142515. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0142515">https://doi.org/10.1371/journal.pone.0142515</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Jansen</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Thamm</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Bock</surname>
							<given-names>CT</given-names>
						</name>
						<name>
							<surname>Scheufele</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Kücherer</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Muenstermann</surname>
							<given-names>D</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>High prevalence and high incidence of co-infection with hepatitis B, hepatitis C, and syphilis and low rate of effective vaccination against hepatitis B in HIV-positive men who have sex with men with known date of HIV seroconversion in Germany</article-title>
					<source>PLoS One</source>
					<year>2015</year>
					<volume>10</volume>
					<issue>11</issue>
					<fpage>e0142515</fpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0142515">https://doi.org/10.1371/journal.pone.0142515</ext-link>
				</element-citation>
			</ref>
			<ref id="B17">
				<label>17</label>
				<mixed-citation>17. Schuelter-Treviso F, Custódio G, Silva ACB, Oliveira MB, Wolfart A, et al. HIV, hepatitis B and C, and syphilis prevalence and co-infection among sex workers in Southern Brazil. Rev Soc Bras Med Trop. 2013;46(4):493-7. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/0037-8682-1364-2013">https://doi.org/10.1590/0037-8682-1364-2013</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Schuelter-Treviso</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Custódio</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Silva</surname>
							<given-names>ACB</given-names>
						</name>
						<name>
							<surname>Oliveira</surname>
							<given-names>MB</given-names>
						</name>
						<name>
							<surname>Wolfart</surname>
							<given-names>A</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>HIV, hepatitis B and C, and syphilis prevalence and co-infection among sex workers in Southern Brazil</article-title>
					<source>Rev Soc Bras Med Trop</source>
					<year>2013</year>
					<volume>46</volume>
					<issue>4</issue>
					<fpage>493</fpage>
					<lpage>497</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/0037-8682-1364-2013">https://doi.org/10.1590/0037-8682-1364-2013</ext-link>
				</element-citation>
			</ref>
			<ref id="B18">
				<label>18</label>
				<mixed-citation>18. Burchell AN, Allen VG, Gardner SL, Moravan V, Tan DH, Grewal R, et al. High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada. BMC Infect Dis. 2015;15:356. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12879-015-1098-2">https://doi.org/10.1186/s12879-015-1098-2</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Burchell</surname>
							<given-names>AN</given-names>
						</name>
						<name>
							<surname>Allen</surname>
							<given-names>VG</given-names>
						</name>
						<name>
							<surname>Gardner</surname>
							<given-names>SL</given-names>
						</name>
						<name>
							<surname>Moravan</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Tan</surname>
							<given-names>DH</given-names>
						</name>
						<name>
							<surname>Grewal</surname>
							<given-names>R</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada</article-title>
					<source>BMC Infect Dis</source>
					<year>2015</year>
					<volume>15</volume>
					<size units="pages">356</size>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12879-015-1098-2">https://doi.org/10.1186/s12879-015-1098-2</ext-link>
				</element-citation>
			</ref>
			<ref id="B19">
				<label>19</label>
				<mixed-citation>19. Zhang C, Ren Q, Chang W. Epidemiological features and risk factors for acquiring hepatitis B, hepatitis C, and syphilis in HIV-infected patients in Shaanxi Province, Northwest China. Int J Environ Res Public Health. 2020;17(6):1990. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/ijerph17061990">https://doi.org/10.3390/ijerph17061990</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zhang</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Ren</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Chang</surname>
							<given-names>W</given-names>
						</name>
					</person-group>
					<article-title>Epidemiological features and risk factors for acquiring hepatitis B, hepatitis C, and syphilis in HIV-infected patients in Shaanxi Province, Northwest China</article-title>
					<source>Int J Environ Res Public Health</source>
					<year>2020</year>
					<volume>17</volume>
					<issue>6</issue>
					<fpage>1990</fpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/ijerph17061990">https://doi.org/10.3390/ijerph17061990</ext-link>
				</element-citation>
			</ref>
			<ref id="B20">
				<label>20</label>
				<mixed-citation>20. Remis RS, Liu J, Loutfy MR, Tharao W, Rebbapragada A, Huibner S, et al. Prevalence of sexually transmitted viral and bacterial infections in HIV-Positive and HIV-negative men who have sex with men in Toronto. PLoS One. 2016;11(7):e0158090. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0158090">https://doi.org/10.1371/journal.pone.0158090</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Remis</surname>
							<given-names>RS</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Loutfy</surname>
							<given-names>MR</given-names>
						</name>
						<name>
							<surname>Tharao</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Rebbapragada</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Huibner</surname>
							<given-names>S</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Prevalence of sexually transmitted viral and bacterial infections in HIV-Positive and HIV-negative men who have sex with men in Toronto</article-title>
					<source>PLoS One</source>
					<year>2016</year>
					<volume>11</volume>
					<issue>7</issue>
					<fpage>e0158090</fpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0158090">https://doi.org/10.1371/journal.pone.0158090</ext-link>
				</element-citation>
			</ref>
			<ref id="B21">
				<label>21</label>
				<mixed-citation>21. Issema R, Songster T, Edgar M, Davis B, Lee T, Harris J, et al. HIV-positive individuals who report being in care are less likely to be co-infected with an STI; an analysis of “Network Testing,” a service program offering HIV and STI testing services to individual at risk for HIV. Open Forum Infect Dis. 2018;5 Suppl 1:S671-2. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/ofid/ofy210.1922">https://doi.org/10.1093/ofid/ofy210.1922</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Issema</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Songster</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Edgar</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Davis</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Lee</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Harris</surname>
							<given-names>J</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>HIV-positive individuals who report being in care are less likely to be co-infected with an STI; an analysis of “Network Testing,” a service program offering HIV and STI testing services to individual at risk for HIV</article-title>
					<source>Open Forum Infect Dis</source>
					<year>2018</year>
					<volume>5</volume>
					<supplement>Suppl 1</supplement>
					<fpage>S671</fpage>
					<lpage>S672</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/ofid/ofy210.1922">https://doi.org/10.1093/ofid/ofy210.1922</ext-link>
				</element-citation>
			</ref>
			<ref id="B22">
				<label>22</label>
				<mixed-citation>22. Hojilla JC, Marcus J, Volk JE, Leyden W, Hare CB, Hechter RC, et al. Alcohol and drug use, partner PrEP use and STI prevalence among people with HIV. Sex Transm Infect. 2020;96(3):184-8. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/sextrans-2019-054049">https://doi.org/10.1136/sextrans-2019-054049</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hojilla</surname>
							<given-names>JC</given-names>
						</name>
						<name>
							<surname>Marcus</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Volk</surname>
							<given-names>JE</given-names>
						</name>
						<name>
							<surname>Leyden</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Hare</surname>
							<given-names>CB</given-names>
						</name>
						<name>
							<surname>Hechter</surname>
							<given-names>RC</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Alcohol and drug use, partner PrEP use and STI prevalence among people with HIV</article-title>
					<source>Sex Transm Infect</source>
					<year>2020</year>
					<volume>96</volume>
					<issue>3</issue>
					<fpage>184</fpage>
					<lpage>188</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/sextrans-2019-054049">https://doi.org/10.1136/sextrans-2019-054049</ext-link>
				</element-citation>
			</ref>
			<ref id="B23">
				<label>23</label>
				<mixed-citation>23. Brignol S, Dourado I, Amorim LD, Kerr LRFS. Vulnerability in the context of HIV and syphilis infection in a population of men who have sex with men (MSM) in Salvador, Bahia State, Brazil. Cad Saude Publica. 2015;31(5):1035-48. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/0102-311X00178313">https://doi.org/10.1590/0102-311X00178313</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Brignol</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Dourado</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Amorim</surname>
							<given-names>LD</given-names>
						</name>
						<name>
							<surname>Kerr</surname>
							<given-names>LRFS</given-names>
						</name>
					</person-group>
					<article-title>Vulnerability in the context of HIV and syphilis infection in a population of men who have sex with men (MSM) in Salvador, Bahia State, Brazil</article-title>
					<source>Cad Saude Publica</source>
					<year>2015</year>
					<volume>31</volume>
					<issue>5</issue>
					<fpage>1035</fpage>
					<lpage>1048</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/0102-311X00178313">https://doi.org/10.1590/0102-311X00178313</ext-link>
				</element-citation>
			</ref>
			<ref id="B24">
				<label>24</label>
				<mixed-citation>24. Shuper PA, Neuman M, Kanteres F, Baliunas D, Joarchi N, Rehm J. Causal considerations on alcohol and HIV /AIDS: a sistematic review. Alcohol Alcohol. 2010;45(2):159-66. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/alcalc/agp091">https://doi.org/10.1093/alcalc/agp091</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Shuper</surname>
							<given-names>PA</given-names>
						</name>
						<name>
							<surname>Neuman</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Kanteres</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Baliunas</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Joarchi</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Rehm</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Causal considerations on alcohol and HIV /AIDS: a sistematic review</article-title>
					<source>Alcohol Alcohol</source>
					<year>2010</year>
					<volume>45</volume>
					<issue>2</issue>
					<fpage>159</fpage>
					<lpage>166</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/alcalc/agp091">https://doi.org/10.1093/alcalc/agp091</ext-link>
				</element-citation>
			</ref>
			<ref id="B25">
				<label>25</label>
				<mixed-citation>25. Kahler CW, Wray TB, Pantalone DW, Kruis RD, Mastroleo NR, Monti PM, et al. Daily associations between alcohol use and unprotected anal sex among heavy drinking HIV-positive men who have sex with men. AIDS Behav. 2014;19(3):422-30. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10461-014-0896-7">https://doi.org/10.1007/s10461-014-0896-7</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kahler</surname>
							<given-names>CW</given-names>
						</name>
						<name>
							<surname>Wray</surname>
							<given-names>TB</given-names>
						</name>
						<name>
							<surname>Pantalone</surname>
							<given-names>DW</given-names>
						</name>
						<name>
							<surname>Kruis</surname>
							<given-names>RD</given-names>
						</name>
						<name>
							<surname>Mastroleo</surname>
							<given-names>NR</given-names>
						</name>
						<name>
							<surname>Monti</surname>
							<given-names>PM</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Daily associations between alcohol use and unprotected anal sex among heavy drinking HIV-positive men who have sex with men</article-title>
					<source>AIDS Behav</source>
					<year>2014</year>
					<volume>19</volume>
					<issue>3</issue>
					<fpage>422</fpage>
					<lpage>430</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10461-014-0896-7">https://doi.org/10.1007/s10461-014-0896-7</ext-link>
				</element-citation>
			</ref>
			<ref id="B26">
				<label>26</label>
				<mixed-citation>26. Hu QH, Xu JJ, Zou HC, Liu J, Zhang J, Ding HB, et al. Risk factors associated with prevalent and incident syphilis among an HIV-infected cohort in Northeast China. BMC Infect Dis. 2014;14:658. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12879-014-0658-1">https://doi.org/10.1186/s12879-014-0658-1</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hu</surname>
							<given-names>QH</given-names>
						</name>
						<name>
							<surname>Xu</surname>
							<given-names>JJ</given-names>
						</name>
						<name>
							<surname>Zou</surname>
							<given-names>HC</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Ding</surname>
							<given-names>HB</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Risk factors associated with prevalent and incident syphilis among an HIV-infected cohort in Northeast China</article-title>
					<source>BMC Infect Dis</source>
					<year>2014</year>
					<volume>14</volume>
					<size units="pages">658</size>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12879-014-0658-1">https://doi.org/10.1186/s12879-014-0658-1</ext-link>
				</element-citation>
			</ref>
			<ref id="B27">
				<label>27</label>
				<mixed-citation>27. Tsachouridou O, Skoura L, Christaki E, Kollaras P, Sidiropoulou E, Zebekakis P, et al.Syphilis on the rise: a prolonged syphilis outbreak among HIV-infected patients in Northern Greece. Germs. 2016;6(3):83-90. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.11599/germs.2016.1093">https://doi.org/10.11599/germs.2016.1093</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Tsachouridou</surname>
							<given-names>O</given-names>
						</name>
						<name>
							<surname>Skoura</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Christaki</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Kollaras</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Sidiropoulou</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Zebekakis</surname>
							<given-names>P</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Syphilis on the rise: a prolonged syphilis outbreak among HIV-infected patients in Northern Greece</article-title>
					<source>Germs</source>
					<year>2016</year>
					<volume>6</volume>
					<issue>3</issue>
					<fpage>83</fpage>
					<lpage>90</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.11599/germs.2016.1093">https://doi.org/10.11599/germs.2016.1093</ext-link>
				</element-citation>
			</ref>
			<ref id="B28">
				<label>28</label>
				<mixed-citation>28. Burchell AN, Allen VG, Gardner SL, Moravan V, Tan DHS, Grewal R, et al; OHTN Cohort Study Team. High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada. BMC Infect Dis. 2015;15:356. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12879-015-1098-2">https://doi.org/10.1186/s12879-015-1098-2</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Burchell</surname>
							<given-names>AN</given-names>
						</name>
						<name>
							<surname>Allen</surname>
							<given-names>VG</given-names>
						</name>
						<name>
							<surname>Gardner</surname>
							<given-names>SL</given-names>
						</name>
						<name>
							<surname>Moravan</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Tan</surname>
							<given-names>DHS</given-names>
						</name>
						<name>
							<surname>Grewal</surname>
							<given-names>R</given-names>
						</name>
						<etal>et al</etal>
						<collab>OHTN Cohort Study Team</collab>
					</person-group>
					<article-title>High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada</article-title>
					<source>BMC Infect Dis</source>
					<year>2015</year>
					<volume>15</volume>
					<size units="pages">356</size>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12879-015-1098-2">https://doi.org/10.1186/s12879-015-1098-2</ext-link>
				</element-citation>
			</ref>
			<ref id="B29">
				<label>29</label>
				<mixed-citation>29. Zoufaly A, Onyoh EF, Tih PM, Awasom CN, Feldt T. High prevalence of hepatitis B and syphilis co-infections among HIV patients initiating antiretroviral therapy in the north-west region of Cameroon. Int J STD AIDS. 2012;23(6):435-8. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1258/ijsa.2011.011279">https://doi.org/10.1258/ijsa.2011.011279</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Zoufaly</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Onyoh</surname>
							<given-names>EF</given-names>
						</name>
						<name>
							<surname>Tih</surname>
							<given-names>PM</given-names>
						</name>
						<name>
							<surname>Awasom</surname>
							<given-names>CN</given-names>
						</name>
						<name>
							<surname>Feldt</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>High prevalence of hepatitis B and syphilis co-infections among HIV patients initiating antiretroviral therapy in the north-west region of Cameroon</article-title>
					<source>Int J STD AIDS</source>
					<year>2012</year>
					<volume>23</volume>
					<issue>6</issue>
					<fpage>435</fpage>
					<lpage>438</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1258/ijsa.2011.011279">https://doi.org/10.1258/ijsa.2011.011279</ext-link>
				</element-citation>
			</ref>
		</ref-list>
	</back>
	<sub-article article-type="translation" id="TRpt" xml:lang="pt">
		<front-stub>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Artigo Original</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Fatores associados à coinfecção HIV/sífilis no início da terapia antirretroviral</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4942-5195</contrib-id>
					<name>
						<surname>Simões</surname>
						<given-names>Luana Andrade</given-names>
					</name>
					<xref ref-type="aff" rid="aff1002"><sup>I</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-3505-4626</contrib-id>
					<name>
						<surname>Mendes</surname>
						<given-names>Jullye Campos</given-names>
					</name>
					<xref ref-type="aff" rid="aff1002"><sup>I</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-7002-4428</contrib-id>
					<name>
						<surname>Silveira</surname>
						<given-names>Micheline Rosa</given-names>
					</name>
					<xref ref-type="aff" rid="aff2002"><sup>II</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-4936-8650</contrib-id>
					<name>
						<surname>Costa</surname>
						<given-names>André Moura Gomes da</given-names>
					</name>
					<xref ref-type="aff" rid="aff3002"><sup>III</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-0760-4424</contrib-id>
					<name>
						<surname>Lula</surname>
						<given-names>Mariana Dias</given-names>
					</name>
					<xref ref-type="aff" rid="aff2002"><sup>II</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-4340-0659</contrib-id>
					<name>
						<surname>Ceccato</surname>
						<given-names>Maria das Graças Braga</given-names>
					</name>
					<xref ref-type="aff" rid="aff2002"><sup>II</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1002">
				<label>I</label>
				<country country="BR">Brasil</country>
				<institution content-type="original">Universidade Federal de Minas Gerais. Faculdade de Farmácia. Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica. Belo Horizonte, MG, Brasil</institution>
			</aff>
			<aff id="aff2002">
				<label>II</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Belo Horizonte, MG, Brasil</institution>
			</aff>
			<aff id="aff3002">
				<label>III</label>
				<country country="BR">Brasil</country>
				<institution content-type="original">Universidade Federal de Minas Gerais. Faculdade de Engenharia. Programa de Pós-Graduação em Engenharia Elétrica. Belo Horizonte, MG, Brasil</institution>
			</aff>
			<author-notes>
				<corresp id="c01002"> Correspondência: Luana Andrade Simões Universidade Federal de Minas Gerais Av. Presidente Antônio Carlos, nº 6.627, sala 1.023-B2 31270-901 Belo Horizonte, MG, Brasil E-mail: lu.unife@gmail.com </corresp>
				<fn fn-type="con">
					<p>Contribuição dos Autores: Concepção e planejamento do estudo: LAS, MGBC, MRS, JCM, MDL, AMGC. Coleta, análise e interpretação dos dados: LAS, MGBC, MRS, JCM, MDL, AMGC. Elaboração ou revisão do manuscrito: LAS, MGBC, MRS, JCM, MDL, AMGC. Aprovação da versão final: LAS, MGBC, MRS, JCM, MDL, AMGC. Responsabilidade pública pelo conteúdo do artigo: LAS, MGBC, MRS, JCM, MDL, AMGC.</p>
				</fn>
				<fn fn-type="conflict">
					<p>Conflito de Interesses: Os autores declaram não haver conflito de interesses.</p>
				</fn>
			</author-notes>
			<abstract>
				<title>RESUMO</title>
				<sec>
					<title>OBJETIVO</title>
					<p> Avaliar a prevalência e os fatores associados à coinfecção HIV/sífilis em pessoas no início da terapia antirretroviral no município de Belo Horizonte, Minas Gerais.</p>
				</sec>
				<sec>
					<title>MÉTODOS</title>
					<p> Foi realizado um corte seccional de um estudo de coorte prospectivo, com pessoas vivendo com HIV, sem tratamento prévio da infecção, em início da terapia antirretroviral, maiores de 16 anos e em acompanhamento em serviços de assistência especializada em HIV/aids de Belo Horizonte. Dados sociodemográficos, comportamentais, clínicos, laboratoriais e relacionados ao tratamento farmacológico foram obtidos por meio de entrevistas, coleta em prontuários clínicos e nos sistemas de informação de controle de medicamentos antirretrovirais e exames laboratoriais. A variável dependente foi o primeiro episódio de sífilis ativa, registrado pelo médico em prontuário clínico, em um período de 12 meses após início da terapia antirretroviral. Os fatores associados à coinfecção HIV/sífilis foram avaliados por meio de regressão logística binária múltipla.</p>
				</sec>
				<sec>
					<title>RESULTADOS</title>
					<p> Dentre os 459 indivíduos avaliados, observou-se uma prevalência de 19,5% (n = 90) de infecções sexualmente transmissíveis, sendo a sífilis (n = 49) a infecção sexualmente transmissível mais frequente nesses indivíduos. A prevalência da coinfecção HIV/sífilis foi de 10,6% (n = 49) e os fatores independentes associados foram o uso de álcool (OR = 2,30; IC95% 1,01–5,26) e ter diagnóstico de outras infecções sexualmente transmissíveis (OR = 3,33; IC95% 1,24–8,95).</p>
				</sec>
				<sec>
					<title>CONCLUSÕES</title>
					<p> Houve alta prevalência de coinfecção HIV/sífilis em pessoas vivendo com HIV em início de terapia antirretroviral em Belo Horizonte. A coinfecção HIV/sífilis foi associada a fatores comportamentais e clínicos, como uso de álcool e diagnóstico de outras infecções sexualmente transmissíveis. O conhecimento prévio sobre os fatores associados à essa coinfecção pode subsidiar as decisões dos profissionais de saúde inseridos no cuidado às pessoas vivendo com HIV, no que diz respeito ao diagnóstico oportuno, orientações, acompanhamento e tratamento adequado, tanto da sífilis quanto do HIV.</p>
				</sec>
			</abstract>
			<kwd-group xml:lang="pt">
				<kwd>Infecções por HIV</kwd>
				<kwd>Sífilis</kwd>
				<kwd>Coinfecção, epidemiologia</kwd>
				<kwd>Fatores de Risco</kwd>
				<kwd>Terapia Antirretroviral de Alta Atividade</kwd>
				<kwd>Estudos Transversais</kwd>
			</kwd-group>
		</front-stub>
		<body>
			<sec sec-type="intro">
				<title>INTRODUÇÃO</title>
				<p>As infecções sexualmente transmissíveis (IST) são consideradas um dos maiores problemas de saúde pública no Brasil e no mundo, e sua prevenção e controle têm benefícios individuais e públicos, dentre eles a diminuição dos riscos de transmissão do vírus da imunodeficiência humana adquirida (HIV)<sup><xref ref-type="bibr" rid="B1">1</xref></sup>.</p>
				<p>As IST atingem um alto índice entre as pessoas sexualmente ativas e ocorrem de forma silenciosa, o que contribui para a sua disseminação e as que possuem modo de transmissão e determinantes sociais mais comuns são a sífilis, causada pelo agente etiológico <italic>Treponema Pallidum,</italic> e a infecção pelo HIV<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup>.</p>
				<p>A infecção pelo <italic>T. pallidum</italic> pode aumentar a carga viral e diminuir o número de linfócitos TCD4+, resultando em uma condição maior de morbidade e mortalidade na pessoa que vive com HIV. Além disso, a presença do HIV pode afetar a transmissão da sífilis, seu curso clínico, resposta ao tratamento e alterar seu diagnóstico<sup><xref ref-type="bibr" rid="B4">4</xref></sup>.</p>
				<p>Em alguns estudos brasileiros, os fatores associados à coinfecção HIV/sífilis foram idade, estado civil, sexo masculino, baixa escolaridade, multiplicidade de parceiros, presença de IST, uso irregular de preservativos, homens que fazem sexo com homens (HSH), dentre outros<sup><xref ref-type="bibr" rid="B5">5</xref></sup>. Em estudos internacionais, os fatores associados foram sexo masculino, migrantes, baixa escolaridade, idade, múltiplos parceiros, uso irregular de preservativos, HSH, uso de drogas ilícitas, presença de IST, dentre outros<sup><xref ref-type="bibr" rid="B10">10</xref></sup>.</p>
				<p>Neste estudo buscou-se avaliar a prevalência da coinfecção HIV/sífilis em indivíduos vivendo com HIV em início de terapia antirretroviral (TARV) em Belo Horizonte, Minas Gerais, e identificar os fatores associados à coinfecção HIV/sífilis.</p>
			</sec>
			<sec sec-type="methods">
				<title>MÉTODOS</title>
				<p>Foi realizado um corte seccional de um estudo de coorte prospectivo, denominada Projeto ECOART “Efetividade da terapia antirretroviral em pessoas vivendo com HIV/tuberculose, HIV/hanseníase ou HIV/leishmaniose visceral no Brasil”. Este projeto foi aprovado pelo comitê de ética em pesquisa da Universidade Federal de Minas Gerais (protocolo CAAE 31192914.3.3001.5124, parecer CEP 769.085) e dos serviços participantes. A pesquisa foi realizada de acordo com as instruções da Resolução 466/2012 do Conselho Nacional de Saúde.</p>
				<p>A seleção da amostra foi não aleatória, pois todos os indivíduos elegíveis foram convidados a participar do estudo. O recrutamento ocorreu entre setembro de 2015 e outubro de 2017.</p>
				<p>O estudo foi realizado em três serviços de assistência especializada (SAE) em HIV/aids do Sistema Único de Saúde (SUS). O serviço I é um ambulatório de assistência de um hospital de referência estadual para o tratamento de doenças infectocontagiosas e dermatologia sanitária; o serviço II é um centro de testagem e aconselhamento (CTA); o serviço III é um SAE referência para o atendimento de doenças infectocontagiosas e parasitárias.</p>
				<p>Os critérios de elegibilidade foram: indivíduos de ambos os sexos, com idade igual ou superior a 16 anos, com diagnóstico de HIV independente do tempo de diagnóstico e da condição clínica do indivíduo, em início de TARV (de zero a seis meses de tratamento), sem tratamento farmacológico prévio da infecção por HIV e que estavam em acompanhamento em um dos três serviços selecionados. Todos os participantes concordaram em participar do estudo e assinaram o termo de consentimento livre e esclarecido.</p>
				<p>A variável dependente foi o primeiro episódio de sífilis ativa registrado pelo médico em prontuário clínico, em um período de 12 meses após início da TARV.</p>
				<p>As variáveis independentes, relacionadas às informações sociodemográficas, comportamentais, clínicas, laboratoriais e ao tratamento farmacológico foram obtidas por meio de entrevistas presenciais, coleta de dados em prontuários clínicos, do Sistema de Controle Logístico de Medicamentos (Siclom) e do Sistema de Controle de Exames Laboratoriais da Rede Nacional de Contagem de Linfócitos CD4+/CD8+ e Carga Viral do HIV (Siscel).</p>
				<p>A idade dos indivíduos foi estratificada em faixas etárias para análise descritiva e como variável contínua na regressão logística. A variável cor ou etnia autodeclarada foi estratificada em branca, preta, amarela, parda ou indígena. O estado civil foi dicotomizado em solteiro(a)/divorciado(a)/viúvo(a) ou casado(a)/união estável. A escolaridade foi categorizada em até 9 anos, de 10 a 12 anos e 13 anos ou mais de escolaridade formal para análise descritiva e em duas categorias para regressão logística (até 9 anos, 10 anos ou mais). Investigou-se também a existência de filhos, se tem ou não emprego, renda própria, plano de saúde privado, local de residência e classe econômica.</p>
				<p>A variável classe econômica foi avaliada de acordo com critérios brasileiros, como alta (A-B), intermediária (C) e baixa (D-E), nos quais os indivíduos são classificados por meio de grupos socioeconômicos por posse de itens de conforto e nível de escolaridade do chefe familiar. Para análise, a variável foi categorizada em alta (A-B) e intermediária-baixa (C-D-E).</p>
				<p>Na avaliação das variáveis comportamentais e hábitos de vida foram analisadas a existência de parceiro sexual fixo em 12 meses após o início da TARV, uso de álcool no mês anterior à entrevista basal, uso de tabaco no momento da entrevista, uso de drogas ilícitas alguma vez na vida (maconha, cocaína, crack e outras, como ecstasy e cola), uso de preservativo no último mês e na última relação sexual.</p>
				<p>Foram analisados o tempo médio do diagnóstico do HIV por autorrelato, classificação clínica inicial e final do indivíduo – categorizadas em A (assintomático), B (sintomático) e C (condição clínica definidora de aids), de acordo com os critérios do Centro de Controle e Prevenção de Doenças (CDC) adaptado<sup><xref ref-type="bibr" rid="B13">13</xref></sup> –, a presença de comorbidades, presença de outras IST prévias e atuais, presença de lesões em mucosas (oral, genital ou anal), carga viral e contagem de linfócitos TCD4, segundo os dados do Siscel, tempo médio de TARV e esquemas terapêuticos, segundo os dados do Siclom. Os esquemas terapêuticos foram categorizados em tenofovir/lamivudina/efavirenz (TLE), tenofovir/lamivudina/dolutegravir (TLD) e outros (qualquer outro esquema antirretroviral). A não adesão foi avaliada por autorrelato, por meio da pergunta “Você deixou de tomar o medicamento nos últimos 15 dias (sim; não)?”.</p>
				<p>A análise descritiva foi realizada por meio de distribuição de frequências para as variáveis categóricas e por meio de medidas de tendência central e de variabilidade para variáveis contínuas. Para a comparação de proporções entre variáveis categóricas utilizou-se o teste qui-quadrado de Pearson ou o exato de Fischer, e para comparação de médias entre variáveis contínuas utilizou-se o teste T. O modelo de regressão logística binária múltipla foi utilizado para avaliar os fatores associados à coinfecção HIV/sífilis.</p>
				<p>Foram realizados testes de colinearidade para todas as variáveis. Os resultados da regressão logística foram apresentados por meio de <italic>odds ratio</italic> (OR), intervalo de confiança de 95% (IC95%) e valor p. As variáveis que apresentaram valor p igual ou inferior a 0,20 na análise bivariada foram incluídas no modelo multivariado. Foi utilizado o método <italic>stepwise backward conditional</italic> para obtenção do modelo final. O teste de Hosmer-Lemeshow e a área abaixo da curva <italic>Receiver Operating Characteristics</italic> (ROC) foram utilizados para verificar o ajuste do modelo. As análises estatísticas foram realizadas utilizando os <italic>softwares Statistical Package for the Social Sciences</italic> (SPSS), versão 22.0, e <italic>R Studio</italic>, versão 4.0.2. Todas as análises foram realizadas com nível de significância de 5%.</p>
			</sec>
			<sec sec-type="results">
				<title>RESULTADOS</title>
				<p>Foram incluídos no estudo 459 indivíduos (<xref ref-type="fig" rid="f01002">Figura</xref>). Dentre as características sociodemográficas da população geral do estudo, observou-se que 81,5% dos indivíduos eram do sexo masculino, com média de idade de 34,7 anos (DP = 10,9), e predominância de faixa etária de 20 a 34 anos (53,4%). A maioria dos indivíduos era solteiro, divorciado ou viúvo (79,7%) e possuía 10 anos ou mais de escolaridade formal (74,3%). Em relação às características comportamentais, 27,5% dos indivíduos faziam uso de tabaco no momento da entrevista, 64,1% faziam uso de álcool em qualquer quantidade no mês anterior à entrevista, 48,1% usaram drogas ilícitas em algum momento na vida. Quanto à potencial fonte de infecção do HIV, mais da metade (51%) era de HSH.</p>
				<p>
					<fig id="f01002">
						<label>Figura</label>
						<caption>
							<title>Diagrama dos indivíduos incluídos no estudo.</title>
						</caption>
						<graphic xlink:href="1518-8787-rsp-56-59-gf01-pt.tif"/>
						<attrib>TARV: terapia antirretroviral.</attrib>
					</fig>
				</p>
				<p>Dentre os participantes, 25,5% relataram não usar preservativos no último mês e 21,4% na última relação sexual. A classificação clínica A (assintomática) foi observada em 63,4% dos indivíduos na primeira consulta e em 80,8% na última consulta. No início do tratamento, a maioria (88,9%) possuía carga viral detectável e, ao final de 12 meses de TARV, apenas 6,8% apresentou carga viral detectável e o percentual de dados faltantes era de 30,5%. Observou-se, no início da TARV, que 26,1% dos indivíduos apresentaram contagem de linfócitos TCD4 abaixo de 200 células/mm<sup><xref ref-type="bibr" rid="B3">3</xref></sup> e 20,9% iniciaram o tratamento com condições clínicas indicadoras de aids. Quanto às características relacionadas ao tratamento, o tempo médio de início da TARV foi de 78,5 dias (DP = 58,97), 63,4% dos indivíduos estavam em uso do esquema TDF/3TC/EFV, 14,8% relataram não adesão ao tratamento e 70,8% tinham acima de três meses de diagnóstico do HIV (Tabela1).</p>
				<p>Observou-se uma prevalência de 19,6% (n = 90) de IST registradas no prontuário clínico, sendo que mais da metade dos registros era de sífilis (n = 49). Dentre os 41 indivíduos que tiveram diagnóstico de outras IST, exceto sífilis, observou-se 9,4% (n = 20) de condiloma e verrugas genitais (anal, vaginal, perianal), 5,6% (n = 12) de herpes genital, 5,6% (n = 12) de hepatite B e C, e 1,4% (n = 3) de outras IST (gonorreia/tricomoníase/IST não especificada). Também foi observado registro de outras lesões em mucosa oral, anal ou genital (5%) descritas como lesão peniana, lesão eritematosa em pênis com prurido, lesão anal e lesão genital (dados não mostrados em tabela).</p>
				<p>A prevalência de indivíduos coinfectados HIV/sífilis neste estudo foi de 10,6% (n = 49). Quanto às características clínicas desses indivíduos coinfectados, observou-se que a maioria apresentou sífilis não especificada (45%), seguida de sífilis latente e latente tardia (26,6%), secundária (14,3%), terciária (neurossífilis e uveítes) (12,1%) e primária (genital primária) (2%). O tempo médio de registro no prontuário clínico da ocorrência do primeiro episódio da sífilis após início da TARV foi de 115,06 dias (DP = 121,26) e a mediana de 53 dias. O exame informado no registro foi o <italic>Venereal Disease Research Laboratory</italic> (VDRL), com 42,9% de resultados reagentes, e 55,1% não possuíam registro de exames. A Penicilina G Benzatina foi prescrita para 85,7% dos indivíduos em tratamento de sífilis e 4,1% utilizaram outros medicamentos como doxiciclina e ceftriaxona. Observou-se ainda 18,4% (n = 9) de outras IST, além da coinfecção, sendo essas, condiloma e verrugas genitais, hepatite B e C e outras (gonorreia/tricomoníase/IST não especificada). Observou-se ainda, que 10,2% tiveram algum registro de lesões em mucosas oral, anal ou genital (dados não mostrados em tabela).</p>
				<p>Conforme demonstrados na <xref ref-type="table" rid="t1002">Tabela 1</xref>, a maioria dos indivíduos coinfectados eram do sexo masculino (93,9%), na faixa etária de 20 a 34 anos (53,1%), pardos ou negros (71,5%), divorciados/solteiros/viúvos (85,7%). Quanto às características comportamentais, a maioria era HSH (69,4%), não possuía parceiro sexual fixo (46,9%) e fazia uso de álcool no mês anterior a entrevista basal (73,5%). Quanto ao uso de preservativo, 26,5% relataram não ter utilizado no último mês e 14,3% não utilizaram na última relação sexual. Houve diferença entre os grupos com e sem coinfecção para as variáveis sexo (p = 0,018), escolaridade formal (p = 0,043), fonte de infecção do HIV (p = 0,025), diagnóstico de outras IST (p = 0,021), tempo médio de diagnóstico do HIV (p = 0,004) e tempo médio de tratamento com antirretrovirais (p = 0,048) (<xref ref-type="table" rid="t1002">Tabela 1</xref>).</p>
				<p>
					<table-wrap id="t1002">
						<label>Tabela 1</label>
						<caption>
							<title>Características sociodemográficas, clínicas, comportamentais, hábitos de vida e tratamento das PVHIV, Belo Horizonte, Minas Gerais, 2015–2018 (n = 459).</title>
						</caption>
						<table frame="hsides" rules="groups">
							<colgroup>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left" rowspan="3">Características</th>
									<th colspan="2" rowspan="2">Total n = 459</th>
									<th colspan="4">Coinfecção HIV/sífilis</th>
									<th rowspan="3">p</th>
								</tr>
								<tr>
									<th colspan="2">Sim n = 49</th>
									<th colspan="2">Não n = 410</th>
								</tr>
								<tr>
									<th>n</th>
									<th>%</th>
									<th>n</th>
									<th>%</th>
									<th>n</th>
									<th>%</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="center" colspan="8"><bold>Sociodemográficas</bold></td>
								</tr>
								<tr>
									<td>Sexo</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,018<sup>a</sup></td>
								</tr>
								<tr>
									<td>Masculino</td>
									<td align="center">374</td>
									<td align="center">81,5</td>
									<td align="center">46</td>
									<td align="center">93,9</td>
									<td align="center">328</td>
									<td align="center">80,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Feminino</td>
									<td align="center">85</td>
									<td align="center">18,5</td>
									<td align="center">3</td>
									<td align="center">6,1</td>
									<td align="center">82</td>
									<td align="center">20,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Idade (anos)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,573</td>
								</tr>
								<tr>
									<td>16–19</td>
									<td align="center">18</td>
									<td align="center">3,9</td>
									<td align="center">1</td>
									<td align="center">2,0</td>
									<td align="center">17</td>
									<td align="center">4,1</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>20–34</td>
									<td align="center">245</td>
									<td align="center">53,4</td>
									<td align="center">26</td>
									<td align="center">53,1</td>
									<td align="center">219</td>
									<td align="center">53,4</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>35–49</td>
									<td align="center">145</td>
									<td align="center">31,6</td>
									<td align="center">14</td>
									<td align="center">28,6</td>
									<td align="center">131</td>
									<td align="center">32,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>≥ 50</td>
									<td align="center">51</td>
									<td align="center">11,1</td>
									<td align="center">8</td>
									<td align="center">16,3</td>
									<td align="center">43</td>
									<td align="center">10,5</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Cor/etnia</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,874<sup>a</sup></td>
								</tr>
								<tr>
									<td>Parda</td>
									<td align="center">222</td>
									<td align="center">48,4</td>
									<td align="center">21</td>
									<td align="center">42,9</td>
									<td align="center">201</td>
									<td align="center">49,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Branca</td>
									<td align="center">108</td>
									<td align="center">23,5</td>
									<td align="center">13</td>
									<td align="center">26,5</td>
									<td align="center">95</td>
									<td align="center">23,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Preta</td>
									<td align="center">106</td>
									<td align="center">23,1</td>
									<td align="center">14</td>
									<td align="center">28,6</td>
									<td align="center">92</td>
									<td align="center">22,4</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Amarela</td>
									<td align="center">15</td>
									<td align="center">3,3</td>
									<td align="center">1</td>
									<td align="center">2,0</td>
									<td align="center">14</td>
									<td align="center">3,4</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Indígena</td>
									<td align="center">3</td>
									<td align="center">0,7</td>
									<td align="center">0</td>
									<td align="center">0,0</td>
									<td align="center">3</td>
									<td align="center">0,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">5</td>
									<td align="center">1,1</td>
									<td align="center">0</td>
									<td align="center">0,0</td>
									<td align="center">5</td>
									<td align="center">1,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Estado civil</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,271</td>
								</tr>
								<tr>
									<td>Solteiro(a)/divorciado(a)/viúvo(a)</td>
									<td align="center">366</td>
									<td align="center">79,7</td>
									<td align="center">42</td>
									<td align="center">85,7</td>
									<td align="center">324</td>
									<td align="center">79,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Casado(a)/união estável</td>
									<td align="center">93</td>
									<td align="center">20,3</td>
									<td align="center">7</td>
									<td align="center">14,3</td>
									<td align="center">86</td>
									<td align="center">21,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Filhos</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,297</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">162</td>
									<td align="center">35,3</td>
									<td align="center">14</td>
									<td align="center">28,6</td>
									<td align="center">148</td>
									<td align="center">36,1</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">297</td>
									<td align="center">64,7</td>
									<td align="center">35</td>
									<td align="center">71,4</td>
									<td align="center">262</td>
									<td align="center">63,9</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Escolaridade formal (anos)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,043<sup>a</sup></td>
								</tr>
								<tr>
									<td>≤ 9</td>
									<td align="center">117</td>
									<td align="center">25,5</td>
									<td align="center">11</td>
									<td align="center">22,4</td>
									<td align="center">106</td>
									<td align="center">25,9</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>10–12</td>
									<td align="center">178</td>
									<td align="center">38,8</td>
									<td align="center">12</td>
									<td align="center">24,5</td>
									<td align="center">166</td>
									<td align="center">40,5</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>≥ 13</td>
									<td align="center">163</td>
									<td align="center">35,5</td>
									<td align="center">26</td>
									<td align="center">53,1</td>
									<td align="center">137</td>
									<td align="center">33,4</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">1</td>
									<td align="center">0,2</td>
									<td align="center">0</td>
									<td align="center">0,0</td>
									<td align="center">1</td>
									<td align="center">0,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Emprego</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,694</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">269</td>
									<td align="center">58,6</td>
									<td align="center">30</td>
									<td align="center">61,2</td>
									<td align="center">239</td>
									<td align="center">58,3</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">190</td>
									<td align="center">41,4</td>
									<td align="center">19</td>
									<td align="center">38,8</td>
									<td align="center">171</td>
									<td align="center">41,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Renda própria</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,087<sup>a</sup></td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">373</td>
									<td align="center">81,3</td>
									<td align="center">41</td>
									<td align="center">83,7</td>
									<td align="center">332</td>
									<td align="center">81,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">85</td>
									<td align="center">18,5</td>
									<td align="center">7</td>
									<td align="center">14,3</td>
									<td align="center">78</td>
									<td align="center">19,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">1</td>
									<td align="center">0,2</td>
									<td align="center">1</td>
									<td align="center">2,0</td>
									<td align="center">0</td>
									<td align="center">0,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Classe Econômica</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,306<sup>a</sup></td>
								</tr>
								<tr>
									<td>Alta (A-B)</td>
									<td align="center">162</td>
									<td align="center">35,3</td>
									<td align="center">20</td>
									<td align="center">40,8</td>
									<td align="center">142</td>
									<td align="center">34,6</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Intermediária (C)</td>
									<td align="center">212</td>
									<td align="center">46,2</td>
									<td align="center">23</td>
									<td align="center">46,9</td>
									<td align="center">189</td>
									<td align="center">46,1</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Baixa (D-E)</td>
									<td align="center">73</td>
									<td align="center">15,9</td>
									<td align="center">4</td>
									<td align="center">8,2</td>
									<td align="center">69</td>
									<td align="center">16,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">12</td>
									<td align="center">2,6</td>
									<td align="center">2</td>
									<td align="center">4,1</td>
									<td align="center">10</td>
									<td align="center">2,4</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Plano privado de saúde</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,511</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">121</td>
									<td align="center">26,4</td>
									<td align="center">11</td>
									<td align="center">22,4</td>
									<td align="center">110</td>
									<td align="center">26,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">338</td>
									<td align="center">73,6</td>
									<td align="center">38</td>
									<td align="center">77,6</td>
									<td align="center">300</td>
									<td align="center">73,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Local de residência</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,656<sup>a</sup></td>
								</tr>
								<tr>
									<td>Belo Horizonte</td>
									<td align="center">404</td>
									<td align="center">88,0</td>
									<td align="center">44</td>
									<td align="center">89,8</td>
									<td align="center">360</td>
									<td align="center">87,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Região metropolitana de Belo Horizonte</td>
									<td align="center">49</td>
									<td align="center">10,7</td>
									<td align="center">4</td>
									<td align="center">8,2</td>
									<td align="center">45</td>
									<td align="center">11,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Outros municípios</td>
									<td align="center">6</td>
									<td align="center">1,3</td>
									<td align="center">1</td>
									<td align="center">2,0</td>
									<td align="center">5</td>
									<td align="center">1,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td align="center" colspan="8"><bold>Comportamentais e hábitos de vida</bold></td>
								</tr>
								<tr>
									<td>Parceiro sexual fixo em 12 meses após a TARV</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,619<sup>a</sup></td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">218</td>
									<td align="center">47,5</td>
									<td align="center">22</td>
									<td align="center">44,9</td>
									<td align="center">196</td>
									<td align="center">47,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">187</td>
									<td align="center">40,7</td>
									<td align="center">23</td>
									<td align="center">46,9</td>
									<td align="center">164</td>
									<td align="center">40,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">54</td>
									<td align="center">11,8</td>
									<td align="center">4</td>
									<td align="center">8,2</td>
									<td align="center">50</td>
									<td align="center">12,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Uso de álcool no mês anterior a entrevista</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,435<sup>a</sup></td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">294</td>
									<td align="center">64,1</td>
									<td align="center">36</td>
									<td align="center">73,5</td>
									<td align="center">258</td>
									<td align="center">62,9</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">162</td>
									<td align="center">35,3</td>
									<td align="center">13</td>
									<td align="center">26,5</td>
									<td align="center">149</td>
									<td align="center">36,3</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">3</td>
									<td align="center">0,7</td>
									<td align="center">0</td>
									<td align="center">0,0</td>
									<td align="center">3</td>
									<td align="center">0,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Uso de tabaco atualmente</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,600</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">126</td>
									<td align="center">27,5</td>
									<td align="center">15</td>
									<td align="center">30,6</td>
									<td align="center">111</td>
									<td align="center">27,1</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">333</td>
									<td align="center">72,5</td>
									<td align="center">34</td>
									<td align="center">69,4</td>
									<td align="center">299</td>
									<td align="center">72,9</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Uso de drogas ilícitas na vida</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,493<sup>a</sup></td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">221</td>
									<td align="center">48,1</td>
									<td align="center">27</td>
									<td align="center">55,1</td>
									<td align="center">194</td>
									<td align="center">47,3</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">236</td>
									<td align="center">51,4</td>
									<td align="center">22</td>
									<td align="center">44,9</td>
									<td align="center">214</td>
									<td align="center">52,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">2</td>
									<td align="center">0,4</td>
									<td align="center">0</td>
									<td align="center">0,0</td>
									<td align="center">2</td>
									<td align="center">0,5</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Uso de preservativo no último mês</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,156</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">248</td>
									<td align="center">54,0</td>
									<td align="center">31</td>
									<td align="center">63,3</td>
									<td align="center">217</td>
									<td align="center">52,9</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">117</td>
									<td align="center">25,5</td>
									<td align="center">13</td>
									<td align="center">26,5</td>
									<td align="center">104</td>
									<td align="center">25,4</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">94</td>
									<td align="center">20,5</td>
									<td align="center">5</td>
									<td align="center">10,2</td>
									<td align="center">89</td>
									<td align="center">21,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Uso de preservativo na última relação sexual</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,383<sup>a</sup></td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">343</td>
									<td align="center">74,7</td>
									<td align="center">41</td>
									<td align="center">83,7</td>
									<td align="center">302</td>
									<td align="center">73,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">98</td>
									<td align="center">21,4</td>
									<td align="center">7</td>
									<td align="center">14,3</td>
									<td align="center">91</td>
									<td align="center">22,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">18</td>
									<td align="center">3,9</td>
									<td align="center">1</td>
									<td align="center">2,0</td>
									<td align="center">17</td>
									<td align="center">4,1</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Fonte de infecção do HIV categoria de exposição</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,025<sup>a</sup></td>
								</tr>
								<tr>
									<td>Homens (HSH)</td>
									<td align="center">234</td>
									<td align="center">51,0</td>
									<td align="center">34</td>
									<td align="center">69,4</td>
									<td align="center">200</td>
									<td align="center">48,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Homens (não HSH)/mulheres</td>
									<td align="center">168</td>
									<td align="center">36,6</td>
									<td align="center">12</td>
									<td align="center">24,5</td>
									<td align="center">156</td>
									<td align="center">38,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">57</td>
									<td align="center">12,4</td>
									<td align="center">3</td>
									<td align="center">6,1</td>
									<td align="center">54</td>
									<td align="center">13,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td align="center" colspan="8"><bold>Clínicas</bold></td>
								</tr>
								<tr>
									<td>Classificação clínica na primeira consulta</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,907<sup>a</sup></td>
								</tr>
								<tr>
									<td>Condições de aids (C)</td>
									<td align="center">96</td>
									<td align="center">20,9</td>
									<td align="center">11</td>
									<td align="center">22,4</td>
									<td align="center">85</td>
									<td align="center">20,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Assintomático (A)</td>
									<td align="center">291</td>
									<td align="center">63,4</td>
									<td align="center">30</td>
									<td align="center">61,2</td>
									<td align="center">261</td>
									<td align="center">63,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sintomático (B)</td>
									<td align="center">67</td>
									<td align="center">14,6</td>
									<td align="center">8</td>
									<td align="center">16,3</td>
									<td align="center">59</td>
									<td align="center">14,4</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">5</td>
									<td align="center">1,1</td>
									<td align="center">0</td>
									<td align="center">0,0</td>
									<td align="center">5</td>
									<td align="center">1,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Classificação clínica na última consulta</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,351<sup>a</sup></td>
								</tr>
								<tr>
									<td>Condições de aids (C)</td>
									<td align="center">35</td>
									<td align="center">7,6</td>
									<td align="center">5</td>
									<td align="center">10,2</td>
									<td align="center">30</td>
									<td align="center">7,3</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Assintomático (A)</td>
									<td align="center">371</td>
									<td align="center">80,8</td>
									<td align="center">42</td>
									<td align="center">85,7</td>
									<td align="center">329</td>
									<td align="center">80,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sintomático (B)</td>
									<td align="center">16</td>
									<td align="center">3,5</td>
									<td align="center">0</td>
									<td align="center">0,0</td>
									<td align="center">16</td>
									<td align="center">3,9</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">37</td>
									<td align="center">8,1</td>
									<td align="center">2</td>
									<td align="center">4,1</td>
									<td align="center">35</td>
									<td align="center">8,5</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Comorbidades</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,951<sup>a</sup></td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">172</td>
									<td align="center">37,5</td>
									<td align="center">18</td>
									<td align="center">36,7</td>
									<td align="center">154</td>
									<td align="center">37,6</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">279</td>
									<td align="center">60,8</td>
									<td align="center">31</td>
									<td align="center">63,3</td>
									<td align="center">248</td>
									<td align="center">60,5</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">8</td>
									<td align="center">1,7</td>
									<td align="center">0</td>
									<td align="center">0,0</td>
									<td align="center">8</td>
									<td align="center">2,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Outras IST (exceto sífilis)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,021</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">41</td>
									<td align="center">8,9</td>
									<td align="center">9</td>
									<td align="center">18,4</td>
									<td align="center">32</td>
									<td align="center">7,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">418</td>
									<td align="center">91,1</td>
									<td align="center">40</td>
									<td align="center">81,6</td>
									<td align="center">378</td>
									<td align="center">92,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Lesões em mucosas</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,086<sup>a</sup></td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">23</td>
									<td align="center">5,0</td>
									<td align="center">5</td>
									<td align="center">10,2</td>
									<td align="center">18</td>
									<td align="center">4,4</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">436</td>
									<td align="center">95,0</td>
									<td align="center">44</td>
									<td align="center">89,8</td>
									<td align="center">392</td>
									<td align="center">95,6</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Antecedentes de IST</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,204</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">134</td>
									<td align="center">29,2</td>
									<td align="center">16</td>
									<td align="center">32,7</td>
									<td align="center">118</td>
									<td align="center">28,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">124</td>
									<td align="center">27,0</td>
									<td align="center">9</td>
									<td align="center">18,4</td>
									<td align="center">115</td>
									<td align="center">28,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">201</td>
									<td align="center">43,8</td>
									<td align="center">24</td>
									<td align="center">49,0</td>
									<td align="center">177</td>
									<td align="center">43,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td align="center" colspan="8"><bold>Laboratoriais</bold></td>
								</tr>
								<tr>
									<td>Carga viral no início da TARV (cópias/ml)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,812<sup>a</sup></td>
								</tr>
								<tr>
									<td>≤ 100 mil</td>
									<td align="center">305</td>
									<td align="center">66,4</td>
									<td align="center">31</td>
									<td align="center">63,3</td>
									<td align="center">274</td>
									<td align="center">66,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>&gt; 100 mil</td>
									<td align="center">114</td>
									<td align="center">24,8</td>
									<td align="center">14</td>
									<td align="center">28,6</td>
									<td align="center">100</td>
									<td align="center">24,4</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">40</td>
									<td align="center">8,7</td>
									<td align="center">4</td>
									<td align="center">8,2</td>
									<td align="center">36</td>
									<td align="center">8,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Carga viral no início da TARV</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,194<sup>a</sup></td>
								</tr>
								<tr>
									<td>Indetectável</td>
									<td align="center">11</td>
									<td align="center">2,4</td>
									<td align="center">3</td>
									<td align="center">6,1</td>
									<td align="center">8</td>
									<td align="center">2,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Detectável</td>
									<td align="center">408</td>
									<td align="center">88,9</td>
									<td align="center">42</td>
									<td align="center">85,7</td>
									<td align="center">366</td>
									<td align="center">89,3</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">40</td>
									<td align="center">8,7</td>
									<td align="center">4</td>
									<td align="center">8,2</td>
									<td align="center">36</td>
									<td align="center">8,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Carga viral após 12 meses de TARV (cópias/ml)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,211<sup>a</sup></td>
								</tr>
								<tr>
									<td>≤ 100 mil</td>
									<td align="center">316</td>
									<td align="center">68,8</td>
									<td align="center">39</td>
									<td align="center">79,6</td>
									<td align="center">277</td>
									<td align="center">67,6</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>&gt; 100 mil</td>
									<td align="center">3</td>
									<td align="center">0,7</td>
									<td align="center">0</td>
									<td align="center">0,0</td>
									<td align="center">3</td>
									<td align="center">0,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">140</td>
									<td align="center">30,5</td>
									<td align="center">10</td>
									<td align="center">20,4</td>
									<td align="center">130</td>
									<td align="center">31,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Carga viral após 12 meses de TARV</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,203</td>
								</tr>
								<tr>
									<td>Indetectável</td>
									<td align="center">288</td>
									<td align="center">62,7</td>
									<td align="center">34</td>
									<td align="center">69,4</td>
									<td align="center">254</td>
									<td align="center">62,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Detectável</td>
									<td align="center">31</td>
									<td align="center">6,8</td>
									<td align="center">5</td>
									<td align="center">10,2</td>
									<td align="center">26</td>
									<td align="center">6,3</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">140</td>
									<td align="center">30,5</td>
									<td align="center">10</td>
									<td align="center">20,4</td>
									<td align="center">130</td>
									<td align="center">31,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Linfócitos TCD4 no início de TARV (células/mm<sup>3</sup>)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,274<sup>a</sup></td>
								</tr>
								<tr>
									<td>&lt; 200</td>
									<td align="center">120</td>
									<td align="center">26,1</td>
									<td align="center">12</td>
									<td align="center">24,5</td>
									<td align="center">108</td>
									<td align="center">26,3</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>200–500</td>
									<td align="center">165</td>
									<td align="center">35,9</td>
									<td align="center">13</td>
									<td align="center">26,5</td>
									<td align="center">152</td>
									<td align="center">37,1</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>&gt; 500</td>
									<td align="center">134</td>
									<td align="center">29,2</td>
									<td align="center">20</td>
									<td align="center">40,8</td>
									<td align="center">114</td>
									<td align="center">27,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">40</td>
									<td align="center">8,7</td>
									<td align="center">4</td>
									<td align="center">8,2</td>
									<td align="center">36</td>
									<td align="center">8,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Linfócitos TCD4 após 12 meses de TARV (células/mm<sup>3</sup>)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,998</td>
								</tr>
								<tr>
									<td>&lt; 200</td>
									<td align="center">27</td>
									<td align="center">5,9</td>
									<td align="center">3</td>
									<td align="center">6,1</td>
									<td align="center">24</td>
									<td align="center">5,9</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>200–500</td>
									<td align="center">139</td>
									<td align="center">30,3</td>
									<td align="center">15</td>
									<td align="center">30,6</td>
									<td align="center">124</td>
									<td align="center">30,2</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>&gt; 500</td>
									<td align="center">155</td>
									<td align="center">33,8</td>
									<td align="center">16</td>
									<td align="center">32,7</td>
									<td align="center">139</td>
									<td align="center">33,9</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">138</td>
									<td align="center">30,1</td>
									<td align="center">15</td>
									<td align="center">30,6</td>
									<td align="center">123</td>
									<td align="center">30,0</td>
									<td>
									</td>
								</tr>
								<tr>
									<td align="center" colspan="8"><bold>Tratamento farmacológico</bold></td>
								</tr>
								<tr>
									<td>Tempo médio do diagnóstico de HIV (mês)</td>
									<td align="center">15,3</td>
									<td align="center">DP = 32,1</td>
									<td align="center">8,5</td>
									<td align="center">DP = 13,4</td>
									<td align="center">16,1</td>
									<td align="center">DP = 33,5</td>
									<td align="center">0,004<sup>b</sup></td>
								</tr>
								<tr>
									<td>Tempo do diagnóstico de HIV (mês)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,018<sup>a</sup></td>
								</tr>
								<tr>
									<td>≤ 3</td>
									<td align="center">131</td>
									<td align="center">28,5</td>
									<td align="center">21</td>
									<td align="center">42,9</td>
									<td align="center">110</td>
									<td align="center">26,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>&gt; 3</td>
									<td align="center">325</td>
									<td align="center">70,8</td>
									<td align="center">27</td>
									<td align="center">55,1</td>
									<td align="center">298</td>
									<td align="center">72,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">3</td>
									<td align="center">0,7</td>
									<td align="center">1</td>
									<td align="center">2,0</td>
									<td align="center">2</td>
									<td align="center">0,5</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Tempo médio de tratamento com TARV (dias)</td>
									<td align="center">78,6</td>
									<td align="center">DP = 59,0</td>
									<td align="center">62,8</td>
									<td align="center">DP = 55,2</td>
									<td align="center">80,4</td>
									<td align="center">DP = 59,2</td>
									<td align="center">0,048<sup>b</sup></td>
								</tr>
								<tr>
									<td>Esquema terapêutico em uso</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,085<sup>a</sup></td>
								</tr>
								<tr>
									<td>TLE</td>
									<td align="center">291</td>
									<td align="center">63,4</td>
									<td align="center">38</td>
									<td align="center">77,6</td>
									<td align="center">253</td>
									<td align="center">61,7</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>TLD</td>
									<td align="center">142</td>
									<td align="center">30,9</td>
									<td align="center">9</td>
									<td align="center">18,4</td>
									<td align="center">133</td>
									<td align="center">32,4</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Outros esquemas</td>
									<td align="center">26</td>
									<td align="center">5,7</td>
									<td align="center">2</td>
									<td align="center">4,1</td>
									<td align="center">24</td>
									<td align="center">5,9</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não adesão à TARV nos últimos 15 dias</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
									<td align="center">0,339</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">68</td>
									<td align="center">14,8</td>
									<td align="center">9</td>
									<td align="center">18,4</td>
									<td align="center">59</td>
									<td align="center">14,4</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">362</td>
									<td align="center">78,9</td>
									<td align="center">35</td>
									<td align="center">71,4</td>
									<td align="center">327</td>
									<td align="center">79,8</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Dados faltantes</td>
									<td align="center">29</td>
									<td align="center">6,3</td>
									<td align="center">5</td>
									<td align="center">10,2</td>
									<td align="center">24</td>
									<td align="center">5,9</td>
									<td>
									</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN1002">
								<p>PVHIV: pessoas vivendo com HIV; HSH: homens que fazem sexo com homens; IST: infecções sexualmente transmissíveis; TLE: tenofovir/lamivudina/efavirenz; TLD: tenofovir/lamivudina/dolutegravir; TARV: terapia antirretroviral; DP: desvio padrão.</p>
							</fn>
							<fn id="TFN2002">
								<p><sup>a</sup> Teste exato de Fischer.</p>
							</fn>
							<fn id="TFN3002">
								<p><sup>b</sup> Teste T para comparação de médias.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>As características que foram significativamente associadas a maior chance de ter a coinfecção HIV/sífilis, na análise bivariada, foram sexo masculino, ser HSH e ter diagnóstico de outras IST. As características associadas a menor chance de ter a coinfecção HIV/sífilis foram maior tempo de TARV e uso do esquema antirretroviral TLD (<xref ref-type="table" rid="t2002">Tabela 2</xref>).</p>
				<p>
					<table-wrap id="t2002">
						<label>Tabela 2</label>
						<caption>
							<title>Análise bivariada dos fatores associados à coinfecção HIV/sífilis, Belo Horizonte, Minas Gerais, 2015–2018 (n = 459)</title>
						</caption>
						<table frame="hsides" rules="groups">
							<colgroup>
								<col/>
								<col/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">Características</th>
									<th>n (%)<sup>a</sup></th>
									<th>OR (IC95%)</th>
									<th>p</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td align="center" colspan="4"><bold>Sociodemográficas</bold></td>
								</tr>
								<tr>
									<td>Sexo</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Masculino</td>
									<td align="center">374 (81,5)</td>
									<td align="center">3,83 (1,16–12,64)</td>
									<td align="center">0,027</td>
								</tr>
								<tr>
									<td>Feminino</td>
									<td align="center">85 (18,5)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Idade (anos)</td>
									<td align="center">459 (100)</td>
									<td align="center">1,01 (0,98–1,03)</td>
									<td align="center">0,674</td>
								</tr>
								<tr>
									<td>Cor/etnia</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Parda/preta</td>
									<td align="center">328 (72,2)</td>
									<td align="center">0,96 (0,50–1,84)</td>
									<td align="center">0,892</td>
								</tr>
								<tr>
									<td>Branca/amarela/indígena</td>
									<td align="center">126 (27,8)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Estado civil</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Solteiro(a)/divorciado(a)/viúvo(a)</td>
									<td align="center">366 (79,7)</td>
									<td align="center">1,59 (0,69–3,67)</td>
									<td align="center">0,275</td>
								</tr>
								<tr>
									<td>Casado(a)/união estável</td>
									<td align="center">93 (20,3)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Filhos</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">162 (35,3)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">297 (64,7)</td>
									<td align="center">1,41 (0,74–2,71)</td>
									<td align="center">0,299</td>
								</tr>
								<tr>
									<td>Escolaridade formal (anos)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>≤ 9</td>
									<td align="center">117 (25,5)</td>
									<td align="center">0,83 (0,41–1,68)</td>
									<td align="center">0,599</td>
								</tr>
								<tr>
									<td>≥ 10</td>
									<td align="center">341 (74,5)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Emprego</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">269 (58,6)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">190 (41,4)</td>
									<td align="center">0,89 (0,48–1,63)</td>
									<td align="center">0,694</td>
								</tr>
								<tr>
									<td>Renda própria</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">373 (81,4)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">85 (18,6)</td>
									<td align="center">0,73 (0,31–1,68)</td>
									<td align="center">0,456</td>
								</tr>
								<tr>
									<td>Classe econômica</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Alta (A-B)</td>
									<td align="center">162 (36,2)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Intermediária-baixa (C-D-E)</td>
									<td align="center">285 (63,8)</td>
									<td align="center">0,74 (0,40–1,37)</td>
									<td align="center">0,343</td>
								</tr>
								<tr>
									<td>Plano privado de saúde</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">121 (26,4)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">338 (73,6)</td>
									<td align="center">1,27 (0,63–2,57)</td>
									<td align="center">0,511</td>
								</tr>
								<tr>
									<td>Local de residência</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Região metropolitana/outros municípios</td>
									<td align="center">55 (12,0)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Belo Horizonte</td>
									<td align="center">404 (88,0)</td>
									<td align="center">1,22 (0,46–3,23)</td>
									<td align="center">0,685</td>
								</tr>
								<tr>
									<td align="center" colspan="4"><bold>Comportamentais e hábitos de vida</bold></td>
								</tr>
								<tr>
									<td>Parceiro sexual fixo em 12 meses após a TARV</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">218 (47,5)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">187 (40,7)</td>
									<td align="center">1,25 (0,67–2,32)</td>
									<td align="center">0,482</td>
								</tr>
								<tr>
									<td>Uso de álcool no mês anterior a entrevista</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">294 (64,5)</td>
									<td align="center">1,60 (0,82–3,11)</td>
									<td align="center">0,167</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">162 (35,5)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Uso de tabaco atualmente</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">126 (27,5)</td>
									<td align="center">1,19 (0,62–2,27)</td>
									<td align="center">0,600</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">333 (72,5)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Uso de droga ilícita na vida</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">221 (48,4)</td>
									<td align="center">1,35 (0,75–2,46)</td>
									<td align="center">0,319</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">236 (51,6)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Uso de preservativo no último mês</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">248 (67,9)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">117 (32,1)</td>
									<td align="center">0,88 (0,44–1,74)</td>
									<td align="center">0,704</td>
								</tr>
								<tr>
									<td>Uso de preservativo na última relação sexual</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">343 (77,8)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">98 (22,2)</td>
									<td align="center">0,57 (0,25–1,31)</td>
									<td align="center">0,182</td>
								</tr>
								<tr>
									<td>Fonte de infecção do HIV – categoria de exposição</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Homens (HSH)</td>
									<td align="center">234 (51,0)</td>
									<td align="center">2,21 (1,11–4,41)</td>
									<td align="center">0,024</td>
								</tr>
								<tr>
									<td>Homens (não HSH)/mulheres</td>
									<td align="center">168 (36,6)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td align="center" colspan="4"><bold>Clínicas</bold></td>
								</tr>
								<tr>
									<td>Classificação clínica na primeira consulta</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Condições de aids (C)</td>
									<td align="center">96 (21,1)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sem aids (A-B)</td>
									<td align="center">358 (78,9)</td>
									<td align="center">1,09 (0,54–2,22)</td>
									<td align="center">0,813</td>
								</tr>
								<tr>
									<td>Classificação clínica na última consulta</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Condições de aids (C)</td>
									<td align="center">35 (8,3)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sem aids (A-B)</td>
									<td align="center">387 (91,7)</td>
									<td align="center">0,73 (0,27–1,98)</td>
									<td align="center">0,538</td>
								</tr>
								<tr>
									<td>Comorbidades</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">172 (38,1)</td>
									<td align="center">0,94 (0,51–1,73)</td>
									<td align="center">0,830</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">279 (61,9)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Outras IST (exceto sífilis)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">41 (8,9)</td>
									<td align="center">2,66 (1,19–5,96)</td>
									<td align="center">0,018</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">418 (91,1)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Lesões em mucosas</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">23 (5,0)</td>
									<td align="center">2,48 (0,88–6,99)</td>
									<td align="center">0,087</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">436 (95,0)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td align="center" colspan="4"><bold>Laboratoriais</bold></td>
								</tr>
								<tr>
									<td>Carga viral no início de TARV</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Detectável</td>
									<td align="center">408 (88,9)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Indetectável</td>
									<td align="center">11 (2,4)</td>
									<td align="center">3,27 (0,84–12,79)</td>
									<td align="center">0,089</td>
								</tr>
								<tr>
									<td>Carga viral após 12 meses de TARV</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Detectável</td>
									<td align="center">31 (6,8)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Indetectável</td>
									<td align="center">288 (62,7)</td>
									<td align="center">0,70 (0,25–1,93)</td>
									<td align="center">0,487</td>
								</tr>
								<tr>
									<td>Linfócito TCD4 no início de TARV (células/mm<sup>3</sup>)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>&lt; 200</td>
									<td align="center">120 (26,1)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>200 a 500</td>
									<td align="center">165 (35,9)</td>
									<td align="center">0,77 (0,34–1,75)</td>
									<td align="center">0,533</td>
								</tr>
								<tr>
									<td>&gt; 500</td>
									<td align="center">134 (29,2)</td>
									<td align="center">1,58 (0,74–3,39)</td>
									<td align="center">0,240</td>
								</tr>
								<tr>
									<td>Linfócito TCD4 após 12 meses de TARV (células/mm<sup>3</sup>)</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>&lt; 200</td>
									<td align="center">27 (5,9)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>200 a 500</td>
									<td align="center">139 (30,3)</td>
									<td align="center">0,97 (0,26–3,60)</td>
									<td align="center">0,961</td>
								</tr>
								<tr>
									<td>&gt; 500</td>
									<td align="center">155 (33,8)</td>
									<td align="center">0,92 (0,25–3,40)</td>
									<td align="center">0,902</td>
								</tr>
								<tr>
									<td align="center" colspan="4"><bold>Tratamento farmacológico</bold></td>
								</tr>
								<tr>
									<td>Tempo diagnóstico HIV (meses)</td>
									<td align="center">456 (100,0)</td>
									<td align="center">0,99 (0,97–1,01)</td>
									<td align="center">0,138</td>
								</tr>
								<tr>
									<td>Tempo de tratamento com antirretrovirais (dias)</td>
									<td align="center">459 (100,0)</td>
									<td align="center">0,99 (0,99–1,00)</td>
									<td align="center">0,050</td>
								</tr>
								<tr>
									<td>Esquema terapêutico em uso</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>TLE</td>
									<td align="center">291 (63,4)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>TLD</td>
									<td align="center">142 (30,9)</td>
									<td align="center">0,45 (0,21–0,96)</td>
									<td align="center">0,039</td>
								</tr>
								<tr>
									<td>Outros esquemas</td>
									<td align="center">26 (5,7)</td>
									<td align="center">0,56 (0,13–2,44)</td>
									<td align="center">0,436</td>
								</tr>
								<tr>
									<td>Autorrelato de não adesão à TARV nos últimos 15 dias</td>
									<td>
									</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">68 (15,8)</td>
									<td align="center">1,43 (0,65–3,12)</td>
									<td align="center">0,375</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">362 (84,2)</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN4002">
								<p>OR: <italic>odds ratio</italic>; IC95%: intervalo de confiança de 95%; TARV: terapia antirretroviral; HSH: homens que fazem sexo com homens; IST: infecções sexualmente transmissíveis; TLE: Tenofovir/Lamivudina/Efavirenz; TLD: Tenofovir/Lamivudina/Dolutegravir.</p>
							</fn>
							<fn id="TFN5002">
								<p><sup>a</sup> Os números variam conforme os dados ignorados.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>Na análise multivariada (<xref ref-type="table" rid="t3002">Tabela 3</xref>) as características independentes associadas à maior chance de coinfecção foram ter diagnóstico de outras IST (OR = 3,33; IC95% 1,24–8,95) e uso de álcool no mês anterior a entrevista (OR = 2,30; IC95% 1,01–5,26). As variáveis sexo e tempo de tratamento com antirretrovirais permaneceram no modelo final, porém não apresentaram significância estatística.</p>
				<p>
					<table-wrap id="t3002">
						<label>Tabela 3</label>
						<caption>
							<title>Regressão logística múltipla dos fatores associados à coinfecção HIV/sífilis, Belo Horizonte, Minas Gerais, 2015–2018 (n = 349a).</title>
						</caption>
						<table frame="hsides" rules="groups">
							<colgroup>
								<col/>
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">Características</th>
									<th>OR (IC95%)</th>
									<th>p</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>Sexo</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Masculino</td>
									<td align="center">3,58 (0,82–15,58)</td>
									<td align="center">0,089</td>
								</tr>
								<tr>
									<td>Feminino</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Uso de álcool no mês anterior a entrevista</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">2,30 (1,01–5,26)</td>
									<td align="center">0,049</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Diagnostico de outras IST (exceto sífilis)</td>
									<td>
									</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Sim</td>
									<td align="center">3,33 (1,24–8,95)</td>
									<td align="center">0,017</td>
								</tr>
								<tr>
									<td>Não</td>
									<td align="center">1,00</td>
									<td>
									</td>
								</tr>
								<tr>
									<td>Tempo de tratamento com antirretrovirais (dias)</td>
									<td align="center">0,99 (0,99–1,00)</td>
									<td align="center">0,066</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN6002">
								<p>OR: <italic>odds ratio</italic>; IC95%: intervalo de confiança de 95%. IST: infecções sexualmente transmissíveis; ROC: <italic>Receiver Operating Characteristics</italic>.</p>
							</fn>
							<fn id="TFN7002">
								<p><sup>a</sup> 110 pacientes com dados faltantes em covariáveis foram excluídos do modelo final.</p>
							</fn>
							<fn id="TFN8002">
								<p>Ajuste do modelo: teste de Hosmer e Lemeshow: X2 = 7,66; df = 8; valor-p = 0,468; área sob a curva ROC = 0,688.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
			</sec>
			<sec sec-type="discussion">
				<title>DISCUSSÃO</title>
				<p>As pessoas vivendo com HIV (PVHIV) atendidas em três serviços de assistência especializada em HIV no SUS, em Belo Horizonte, que estavam em início de TARV apresentaram alta prevalência de coinfecção por IST (19,6%), sendo a sífilis (10,6%) a mais prevalente. Destaca-se que a prevalência global estimada de sífilis entre homens e mulheres, sem a infecção por HIV, é de 0,5% no Brasil<sup><xref ref-type="bibr" rid="B1">1</xref></sup>. As características associadas independentemente com a coinfecção HIV/sífilis foram diagnóstico de outras IST e uso de álcool no mês anterior à entrevista.</p>
				<p>A prevalência e os fatores associados à sífilis nas PVHIV apresentam variações, tanto em estudos brasileiros quanto internacionais. Essa variação depende do tipo de população, como por exemplo a população chave (transgêneros, profissionais do sexo, pessoas que usam drogas injetáveis, HSH e prisioneiros – e seus parceiros) que têm prevalência maior de coinfecção HIV/sífilis<sup><xref ref-type="bibr" rid="B14">14</xref></sup>.</p>
				<p>A prevalência de coinfecção HIV/sífilis observada neste estudo foi menor que aquela encontrada em um estudo realizado em Mkushi, na Zâmbia, no qual os autores observaram 40,5% de coinfecção HIV/sífilis em indivíduos recém-diagnosticados com HIV iniciando TARV<sup><xref ref-type="bibr" rid="B15">15</xref></sup>. Também foi menor do que a prevalência encontrada em um estudo prospectivo multicêntrico com HSH, realizado na Alemanha, que foi de 39,6%<sup><xref ref-type="bibr" rid="B16">16</xref></sup>. Em outro estudo realizado no Brasil, com trabalhadores do sexo, a prevalência encontrada foi de 30,8%<sup><xref ref-type="bibr" rid="B17">17</xref></sup>.</p>
				<p>Semelhante a outros estudos<sup><xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref></sup>, também observamos que ter diagnóstico de outras IST apresentaram associação independente com maior chance de coinfecção HIV/sífilis. Esse resultado pode indicar que o comportamento sexual de risco das PVHIV pode contribuir para a disseminação da infecção pelo HIV e impactar no controle da sua transmissão.</p>
				<p>As IST são transmitidas por contato sexual sem o uso de preservativo, uma medida preventiva importante entre casais HIV sorodiscordantes e soroconcordantes para evitar a transmissão de outras IST. Um estudo encontrou a presença de sífilis, citomegalovírus, papilomavírus humano (HPV) e herpes simples nos HSH que vivem com HIV<sup><xref ref-type="bibr" rid="B20">20</xref></sup>. Ainda, de forma semelhante em nosso estudo, foi observada a presença das IST condiloma e verrugas genitais, herpes genital, hepatite B e C e outras (gonorreia/tricomoniase/IST não especificada), além de lesões em mucosas anal e genital.</p>
				<p>As PVHIV apresentam um risco maior de coinfecção com hepatites e sífilis do que a população em geral. As infecções bacterianas, os protozoários, a herpes genital e infecções sexuais anteriores, foram descritas como fatores de risco para a coinfecção HIV/sífilis. As IST podem apontar um comportamento sexual de risco das PVHIV, elevar a possibilidade de infecção do HIV e impactar no controle da sua transmissão<sup><xref ref-type="bibr" rid="B20">20</xref></sup><sub>.</sub></p>
				<p>Em outro estudo foram analisados os fatores associados à coinfecção HIV/IST em 295 PVHIV, em que 37% tiveram ao menos uma IST. Dentre as IST citadas, 32% delas eram sífilis, 16% de gonorreia e 8% de clamídia. A alta prevalência de IST entre PVHIV sugere a necessidade de testagem, prevenção e tratamento adequado nessa população<sup><xref ref-type="bibr" rid="B21">21</xref></sup>.</p>
				<p>Neste estudo, o relato de uso de álcool anterior a entrevista apresentou associação com maior chance de coinfecção HIV/sífilis, resultado semelhante a outros estudos<sup><xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref></sup>. O consumo de álcool é um grave problema de saúde pública, visto que pode levar o indivíduo à adoção de práticas sexuais de risco e contribuir para a carência de hábitos preventivos às IST, como não usar preservativo, trocar de parceiros com frequência e praticar sexo em grupo ou anal, acarretando maiores chances de contrair sífilis e outras IST. Esse cenário colabora para a manutenção da cadeia de transmissão das IST na PVHIV<sup><xref ref-type="bibr" rid="B24">24</xref></sup><sub>.</sub></p>
				<p>O álcool é uma substância que deprime o sistema nervoso central e atua reduzindo a ansiedade e a inibição. A convicção de que usar álcool aumenta o prazer, faz com que seja utilizado antes ou durante as práticas sexuais. Estima-se que o consumo de álcool entre PVHIV é 2,5 vezes maior do que no restante da população. O uso de álcool e drogas aumenta em até seis vezes o risco de pessoas com HIV praticarem sexo sem preservativo e de terem múltiplos parceiros. Em um estudo foi estimado a prevalência de 28,6% de uso abusivo de álcool entre pessoas que vivem com HIV<sup><xref ref-type="bibr" rid="B25">25</xref></sup><sub>.</sub></p>
				<p>Maior tempo de TARV apresentou associação à menor chance de coinfecção HIV/sífilis e permaneceu no modelo final devido a maior robustez, embora não tenha apresentado significância estatística. Cabe ressaltar que são controversos os resultados dos estudos nos quais avaliou-se a associação entre uso de TARV e transmissão de IST.</p>
				<p>Em um estudo de coorte retrospectiva encontrou-se associação do uso de TARV com menor chance de coinfecção HIV/sífilis no início do tratamento, corroborando com o resultado encontrado nesta pesquisa. Em contrapartida, o uso da TARV foi associado a maior chance de coinfecção nos indivíduos que tiveram soroconversão de sífilis durante o acompanhamento desses indivíduos<sup><xref ref-type="bibr" rid="B26">26</xref></sup>. No estudo de Tsachouridou et al.<sup><xref ref-type="bibr" rid="B27">27</xref></sup> os indivíduos em uso de TARV apresentaram 2,4 vezes mais chance de ter coinfecção HIV/sífilis. Esses estudos apontam que as vantagens do uso dos antirretrovirais refletem no comportamento sexual das PVHIV ao não usarem o preservativo por se sentirem, provavelmente, seguros quanto a não transmissão do vírus HIV<sup><xref ref-type="bibr" rid="B27">27</xref></sup>.</p>
				<p>Em nosso estudo, a variável sexo masculino apresentou associação para maior chance de coinfecção HIV/sífilis e permaneceu no modelo final devido à robustez do modelo, embora não tenha apresentado significância estatística. Esse resultado foi consonante ao de outros estudos que apontaram maior risco de coinfecção em pessoas do sexo masculino<sup><xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref></sup>.</p>
				<p>A prevalência da sífilis e as distintas IST encontradas neste estudo podem refletir o uso inconsistente do preservativo e de outras ações de prevenção dessas infecções. O conhecimento sobre os fatores associados à prevalência da coinfecção HIV/sífilis pode subsidiar a tomada de decisões dos profissionais inseridos no cuidado às PVHIV. O acompanhamento e tratamento adequado da sífilis e IST requerem orientações de práticas sexuais seguras para prevenção dessas coinfecções nas PVHIV.</p>
				<p>As limitações do estudo dizem respeito à utilização de dados secundários com elementos faltantes de registros gerais sobre as informações clínicas e sobre os exames laboratoriais dos indivíduos.</p>
				<p>Este estudo tem como pontos fortes a qualidade e tratamento dos dados primários coletados, com análise de confiabilidade de 10% da amostra total para coleta e digitação. Ressalte-se a alta concordância interdigitador perfeita avaliada pela estatística Kappa, a inclusão abrangente de variáveis explicativas e a robustez do modelo final.</p>
				<p>Conclui-se que a prevalência de IST registradas foi alta e a sífilis foi a coinfecção mais prevalente. O uso de álcool e o diagnóstico de outras IST foram associadas a maior chance de coinfecção HIV/sífilis nessa população.</p>
			</sec>
		</body>
	</sub-article>
</article>